Rheumnow Podcast

Influential Rheumatoid Factors(5/8/2026)

Fri, 08 May 2026 13:14:51 -0500

Dr Jack Cush reviews the news and journal reports from last weekon rheumnow.com

Great Lectures; Great Presentations

Fri, 01 May 2026 06:29:01 -0500

Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.

DERM on RheumNow (April 2026)

Fri, 01 May 2026 06:08:20 -0500

Features Dr. Jack Cush, Editor at RheumNow.com.

Show Notes:

Chinese target emulation trial of MDA-5+, dermatomyositis w/ ILD. 106 Rx w/ UPA & 328 w/ TOFA. 6-month lung transplantation-free survival 72% vs 67% (UPA v TOFA). UPA non-inferior to TOFA in MDA5+DM-ILD https://t.co/BBAfbM06AM

In 2025 DTC TV ad spending by top 10 incr to $2.67 billion (up from $2.1 B). Rheum Drugs in top 3: 1. Skyrizi $440 million 2. Tremfya $431 M 3. Rinvoq $376 M https://t.co/EsWgUqUy9Z

2. Dermatology Salaries 2025 – Dermatology is top 10 at $448K according to Medscape; expected to go down -1% in 2026; derms made up 2% of survey group 37K MDs

3. Itch is common in Scleroderma (SSc) and not related to Dz duration. Study of 2173 Pts (~20K itch assessments), 87 F; mean age 55 yrs; 40% w/ diffuse SSc. Itch (moderate 4/10) seen in ~35% at all times https://t.co/QnT8d0xA5Z

4. Asia-Pacific Lupus study of Mucocutaneous activity (MC-A) in 4102 SLE pts. 36% had MC-A (rash 1055; alopecia 731; m ulcers 352); 15% persistently. MC-A assoc w/ W, smoking, +serologies, vasculitis, myositis, serositis, nephritis, NP-SLE https://buff.ly/D5fXJdY

5. Predictors of Calcinosis Cutis in Systemic Sclerosis

6. AFFINITY Study - Combination Biologic Therapy in PsA A pilot trial assessed the efficacy and safety of the guselkumab+golimumab (COMBO) combination versus GUS monotherapy in active PsA (failing a prior tumor necrosis factor inhibitor (TNFi-IR) and showed superiority in ACR 50 https://t.co/f2CB8FnZMB

7. AAD 2026 Annual Mtg presents new data on another TYK2 inhibitor. In 2 phase 3 RCTs (ONWARD1 ONWARD2) envudeucitinib was superior to placebo & apremilast in 1700 plaque psoriasis pts https://t.co/DPlzDw5m7N

8. Among 1074 #PsA tested annually, RF positivity was found in 16.1% overall (5.1% RF+ at baseline). RF+ rediced odds of MDA (OR 0.53) w/ incr risk of bDMARD discontinuation (OR 2.65) https://buff.ly/BsM7NKQ

9. The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis - Review

10. Ixekizumab With Tirzepatide Efficacy in Obese Psoriatic Arthritis

11. Brepocitinib in Dermatomyositis

Follow the Money (4.23.2026)

Fri, 24 Apr 2026 11:09:02 -0500

Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week.

Prescribing Lessons (4.17.2026)

Fri, 17 Apr 2026 10:18:57 -0500

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Top Four and More (4.10.2026)

Fri, 10 Apr 2026 14:14:13 -0500

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week - including his top four favorite subjects.

Whats New PsA? (4.3.2026)

Fri, 03 Apr 2026 10:59:40 -0500

Dr. Jack Cush reviews the news and major articles from this week, including FDA safety warnings, reports from AAD, PsA trials.

PsA GRAPPA Domains: Outcomes With a JAKi

Wed, 01 Apr 2026 16:52:42 -0500

Dr. Schwartzman and Dr. Ruderman discuss how PsA disease activity across GRAPPA domains may guide treatment decisions, sharing both the evidence for and their experience with a JAKi across domains.
Sponsored by AbbVie Medical Affairs + Health Impact 

Moral Distress (3.27.2026)

Fri, 27 Mar 2026 09:19:03 -0500

Dr. Jack Cush reviews the journal reports and news from RheumNow.com. This week we discuss moral distress, FM in PsA, Lyme Vax is back & hidden but tangible benefits of the MDHAQ.

DERM on RheumNow Podcast (March 2026)

Fri, 27 Mar 2026 09:15:43 -0500

This month: Multiple FDA regulatory decisions germane to dermatology, psoriasis and lupus; and Eosinophilic Fasciitis (EF) reminder and should you worry about fibromyalgia?
Show Notes:
1. FDA Approves Icotrokinra for Plaque Psoriasis The FDA approved an oral IL-23 inhibitor, icotrokinra (Icotyde), for use in moderate-to-severe plaque psoriasis in adults and children 12 years of age and older who are candidates for systemic therapy or phototherapy, according to a https://t.co/q5b3TceFHx
2. FDA has approved secukinumab (Cosentyx) for use pediatric patients (aged 12yrs) with moderate to severe hidradenitis suppurativa https://t.co/oX4LGU16QP

3. FDA has accepted the supplemental biologics license application for use of interleukin-23 inhibitor tildrakizumab (Ilumya; Sun Pharma) in active psoriatic arthritis (PsA) in adults. https://t.co/cwqz9DoWsL https://t.co/ut0A4MwqW7

4. TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active PsA based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. https://t.co/a6rmortnoS

5.vUCB announced topline results of the BE-BOLD head-to-head study where bimekizumab (IL-17i) was superior to risankizumab (IL-23i) study; 553 active PsA in achieving an ACR50 response at 16 weeks. Enrolled PsA pts were either bilogic naïve or who had previous exposure to 1 TNFi

6. Retrospective TriNetX Network cohort study of adult PsA (N 123,031) pts, propensity- matched to non-PsA controls. PsA had signif higher CV morbidity: MACE (HR 1.74); mortality (HR 1.95); CHF (HR 1.96), MI (HR 1.71), & CVA (HR 1.49). bDMARDs reduced MACE (HR 0.95) & mortality (HR 0.92) vs csDMARDs https://t.co/bHrq9KpwBM

7. Prevalence of fibromyalgia in PsA = 18%. FM-PsA pts have higher scores Dz activity scores from FM, rather than inflammation. Fibromyalgia is assoc w/ worse disease outcomes, including failure to achieve low disease activity state and poorer response to therapy. https://t.co/utQRXPmpDs

8. JAMA Patient Education Page on JAMA Eosinophilic Fasciitis (EF). EF is rare, but begins with swelling and redness of the arms and/or legs. Later the skin thickens and develops the peau d' orange appearance. EF does not involve fingers or toes, & doesnt have Raynauds https://t.co/WEFFITtmQC

9. REVEAL, a 5-yr real-world study of 236 SLE pts initiating anifrolumab (basekbube SLEDAI-2K 7 for mucocutaneous (67%) & MSK (49%) dz. At 6 months, 26% achieved remission, 66% reached LLDAS, and 57% achieved LLDAS5. Authors claim rapid onset of action https://t.co/16OQatOcPj https://t.co/mU9aciCNcH

10. Update on FDA complete response letter to AZ regarding BLA hold for anifrolumab (Saphnelo) for SC use in SLE. CRL originally issued 10/10/25, but announced 2/3/26. FDA CRL cites critical data quality w/ key analyses in SC-TULIP study. A BLA decision expected in 1st half of 2026 https://t.co/zuwtsdL6I9

11. NEJM: Obinutuzumab in Active Systemic Lupus Erythematosus https://rheumnow.com/news/nejm-obinutuzumab-active-systemic-lupus-erythematosus

Pitfalls in Rheumatology (3.20.2026)

Fri, 20 Mar 2026 13:09:14 -0500

Dr. Jack Cush reviews the regulatory actions, news and journal reports from this past week on RheumNow.com

STEP Talks from RNL26 Part #2

Fri, 20 Mar 2026 06:34:12 -0500

STEP: Obesity and Inflammation: Weight management in Rheumatology. Dr. Uzma Haque
STEP: Mitigating Risk for Rheumatic Disease Patients Undergoing Orthopedic Surgery. Dr. Susan Goodman

STEP Talks from RNL26 Part #1

Fri, 20 Mar 2026 06:26:25 -0500

STEP: Disease Modification in OA - Dr. Tuhina Neogi
STEP: History of Gout - Dr. Robert Terkeltaub

Rheumatoid Arthritis Faculty Panel Q&A

Fri, 20 Mar 2026 06:19:47 -0500

Rheumatoid Arthritis Faculty Panel Q&A

ILD in RA - Recent Advances. Dr. Jeffrey Sparks

Fri, 20 Mar 2026 06:15:51 -0500

ILD in RA - Recent Advances. Dr. Jeffrey Sparks

The Mucosal Hypothesis of Rheumatoid Arthritis. Dr. Kristin Demoruelle

Fri, 20 Mar 2026 06:08:08 -0500

The Mucosal Hypothesis of Rheumatoid Arthritis. Dr. Kristin Demoruelle

Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau? Dr. Elena Myasoedova

Fri, 20 Mar 2026 06:01:16 -0500

Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau? Dr. Elena Myasoedova

Poets Know It (3.13.2026)

Fri, 13 Mar 2026 11:13:41 -0500

Dr. Jack Cush reviews the news, regulatory decisions and new journal articles.

UBER Rheumatology Ride (3.6.2026)

Fri, 06 Mar 2026 16:46:41 -0600

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com

Early Decisions and Impact: Risankizumab in Bio-Naive Patients With PsA Sponsored by AbbVie Medical Affairs + Health Impact

Mon, 02 Mar 2026 05:11:55 -0600

DERM on RheumNow PODCAST (February 2026)

Sat, 28 Feb 2026 14:19:44 -0600

SHOW NOTES
FDA sent a complete response letter to AstraZeneca on their application (BLA) for anifrolumabs (Saphnelo) subcutaneous use in SLE. Despite a positive TULIP-SC trial & EU approval of SC-anifrolumab, FDA & sponsor still have to work things out. CRL reasons are unknown https://t.co/3dNwEyolrj

Review of Calcinosis Cutis - Surgical intervent. most effective (excision, curettage, laser ablation, etc). Medical measures inconsistently, partially effective, best if used early & localized (CCB, TCN, probenecid, immunomodulation, biologics, colchicine, NA thiosulfate, & JAKi https://t.co/rv0hQBv6nX

Systematic Review of Targeted Rx for Systemic Sclerosis: from 32 RCTs & 2036 pts Rx w/ 23 targeted agents. Guselkumab had greatest effect on mRSS, followed by tofacitinib, inebilizumab, & baricitinib. For FVC, B-cell Rx (belimumab, RTX) had highest efficacy https://buff.ly/vHOSRws

Dermatomyositis outcomes w/ 2475 pts (claims) & 1196 pts (EHR). Half had myositis panels & 35% had + MSAbs. Steroid use common in 69% & 74%. HCQ, MTX, MMF. Outocmes (per 1000PYs) wereL all-cause hospitalisation 92, malignancy 15.3, ILD 6.4, and myocarditis 2.1 https://t.co/DJqKGNGX76
Danish DERMBIO registry of psoriasis pts Rx w/ biologics. Among 3790 bionaive pts ustekinumab had best 1-5 yr survival vs (ADA & SEC). In 3403 bioexperienced pts, bimekizumab, guselkumab, & risankizumab had highest 2-year drug survival rate. https://t.co/TInyLPMYkb

Real-world study of 1202 #PsA pts shows that secukinumab retention rates were lower w/ smoking (79%/73%/72% in never/former/current smokers) but not w/ obesity (72%/77%/77% in normal/overweight/obese), Adh HR signif. higher w/ former (1.32) & current smokers (1.27) https://t.co/1REWmod73W

Together PSO Trial - Combination Ixekizumab and Tirzepatide Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over https://t.co/YWCjN2NyGM

SATISFACTION (2.27.2026)

Fri, 27 Feb 2026 16:22:23 -0600

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Referral Rules to Live By (2.20.2026)

Fri, 20 Feb 2026 13:58:55 -0600

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Highlights include referral rules, combination biiologics in psoriasis and don't use JAK inhibitors in pregnancy.

Maui Potpourri (2.13.2026)

Fri, 13 Feb 2026 18:31:35 -0600

Dr.Jack Cush reviews the hot item takeaways from last weeks RheumNow.Live 2026
Diet & Obesity Management in Rheumatology - Uzma Haque, MD
Mitigating risk for Rheum patients undergoing orthopedic surgery - Susan Goodman, MD
Paradoxical skin reactions – Dr. Joseph Merola
Mortality in RA - Elena Myasoedova, MD
The Mucosal Hypothesis to RA - Kristin Demourelle, MD
Advances in ILD - Jeffrey Sparks, MD
Seronegative vs. Seropositive RA - Jack Cush, MD

ANA Pollution (2.06.2026)

Fri, 06 Feb 2026 06:18:58 -0600

Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com

DERM on RheumNow PODCAST (January 2026)

Mon, 02 Feb 2026 06:36:22 -0600

Features Dr. Jack Cush, Editor at RheumNow.com.

SHOW NOTES
Lupus Accelerating Breakthroughs Consortium commissioned a stakeholders group (including the FDA) to assess drug development in Cutaneous lupus CLE), and they have endorsed CLASI (CLE Dz Area & Severity Index) as the outcome measure for CLE clinical trials. https://t.co/q7If97AHBa

PAPA Syndrome: When Sterile Inflammation Mimics Infection (Pyogenic Arthritis, Pyoderma gangrenosum, Acne) •A rare monogenic autoinflammatory disease •Caused by gain-of-function mutations in PSTPIP1 🧠 Pathophysiology •Mutant PSTPIP1 - increased interaction with pyrin https://t.co/tJ4INdgfky

Turkish study of 128 Psoriatics (62 PSO, 66 PsA) found more periodontitis in PsA vs PSO (47% vs 31%; P=.058). Assoc. w/ Signif. higher levels of Dz activity seen for PSO (CPDAI: OR 1.38; P = .001) & enthesitis (MASES: OR 1.39; P .001) if periodontitis present in PsA patients. https://t.co/d8OfarFWeG

Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/EzaqS5q096

Did you know theres a Subcutaneous (SC) rituximab (Hycela)? Its same RTX but combined w/ hyaluronidase, faster 5-7 minute injection Vs hours for IV RTX. FDA approved 2017 for Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL). Give 1st dose IV, then use SC RTX. https://t.co/piQ2ZhAOyf

German psoriasis registry PsoBest reports on 595 Rx w/ apremilast (417 APR monotherapy). Compared to Ptx Rx w/ other DMARDs/biologic drugs, APR pts higher age, more comorbidities. Nonserious AEs: ineffectiveness (14%), diarrhea (9%), nausea (7%), HA (6%). https://t.co/TviJmM7Fr9 https://t.co/tY89oHgUgV

DMARD Responses in Localized Scleroderma – MMF = MTX ~114 pts

Advanced Practitioner Biologic Prescriptions for Psoriasis Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA https://t.co/3NtntmpSPV

GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant https://t.co/8fOXWULH7w

RheumNow Live Preview (1.30.2026)

Fri, 30 Jan 2026 15:31:32 -0600

Dr. Jack Cush reviews the news and journal reports from RheumNow.com
Top 5 reasons to attend RheumNow Live 2026
1. Its cold and far, but you can be there virtually, online
2. Ffull access to handouts, slides & downloads
3. Saturday concert with Colin Boyd
4. Rohit Agarwal does TWO STEP talks!
5. Download 400+ rheumatology review Questions

Focus on Guidelines

Wed, 28 Jan 2026 09:16:44 -0600

Join us for our next webinar: Focus on Guidelines. Panelists will discuss their approaches to a range of difficult cases in multiple areas, including rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis and vasculitis, and discuss how they apply the guidelines in everyday practice. You’ll hear different perspectives and practical tips you can use in clinic.

Panelists:
Audrey Gibson, PA-C
Benjamin A. Smith, PA-C
Jack Cush, MD

Following the discussion, join a live Q & A with the panelists. Register now to reserve your spot!

This is our second Tuesday Night Rheumatology this month as part of our Mission: APP Partners in Care campaign

Emergencies, Independence & Hemorrhage (1.23.2026)

Fri, 23 Jan 2026 08:52:40 -0600

Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com

2025 Rheumatology Year in Review (1.16.26)

Fri, 16 Jan 2026 16:58:07 -0600

Dr. Jack Cush reviews rheumatology's highlights, advances and noteworthy trends from the past year - 2025!

APP Podcast Series Part Two

Thu, 15 Jan 2026 09:29:58 -0600

1- Sex & the Rheum Patient (12:17)
2- Pain Management (17.58)
3- Lifestyle (15.38)

APP Podcast Series Part One

Thu, 15 Jan 2026 09:26:23 -0600

This podcast is part one of the Mission: APP Partners in Care Therapeutic Update Series called Underserved and under-treated. This podcast includes videos from: Daric Mueller, PA-C, Rachel Busch-Feuer, DNP, Betsy Kirchner, DNP, Lindsay Tom, PA-C and Vanessa Hill, NP-C

2026 Resolutions (1.9.2026)

Fri, 09 Jan 2026 17:19:07 -0600

Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!

DERM on RheumNow Podcast (December 2025)

Fri, 02 Jan 2026 19:25:41 -0600

Features Dr. Jack Cush

Comorbidity and Health Management

Wed, 24 Dec 2025 07:59:43 -0600

Panelists: Vanessa Hill, NP-C Lindsay Tom, PA-C Barb Slusher Jack Cush, MD

Telling You Where to Go (12.19.2025)

Fri, 19 Dec 2025 06:26:57 -0600

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Who would've thunk - a PsA FMF connection? Labs to diagnose SSc-ILD? IgA-RF may be important or RZV may not work in JAK inhibitor treated patients?

APP Controversies and Misconceptions

Wed, 17 Dec 2025 07:52:21 -0600

Join us for our third webinar this month, discussing APP Controversies and Misconceptions. Panelists will cover a range of topics, including APP roles impact; models of care; independence; seeing new patients and complex cases; and more.

Panelists:
Daric A. Mueller, PA-C
Lisa Carnago, MSN, FNP-C, RN
Jack Cush, MD

Reefer Madness (12.12.2025)

Fri, 12 Dec 2025 07:03:04 -0600

Dr. Jack Cush reviews the news, journal and regulatory reports from this past week on RheumNow.com. B cell drugs in SLE and ITP, biomarkers in GCA & PSS and great videos by APPs.

Cases & Guidelines

Wed, 10 Dec 2025 07:53:07 -0600

Panelists:
Audrey Gibson, PA-C
Benjamin A. Smith, PA-C
Jack Cush, MD

Following the discussion, join a live Q & A with the panelists. Register now to reserve your spot!

This is our second Tuesday Night Rheumatology this month as part of our Mission: APP Partners in Care campaign

Preview of RheumNow Live 2026

Wed, 10 Dec 2025 06:40:44 -0600

Drs. Jack Cush and Artie Kavanaugh preview the upcoming RNL 2026 meeting in Dallas, TX on February 7 & 8, 2026. Register at RheumNow.Live Below is the program: Saturday, February 7, 2026, 7:50 - 8:00 am Welcome & Introductions Drs. Cush and Kavanaugh 8:00 - 10:00 am POD I - Rheumatoid Arthritis: Achieving Better Outcomes 8:00 – 8:30 am Mortality in RA: A Story of Decline, Delay, or Plateau? Elena Myasoedova, MD 8:30 – 9:00 am The Mucosal Hypothesis of Rheumatoid Arthritis Kristen Demoruelle, MD 9:00 – 9:30 am ILD in RA – Recent Advances Jeffrey Sparks, MD 9:30 – 10:00 am Rheumatoid arthritis Faculty Q&A 10:00 - 10:15 am STEP 1: Placebos in Rheumatology Andreas Kerschbaumer, MD 10:15 -10:30 am STEP 2: Disease Modification in Osteoarthritis Tuhina Neogi, MD PhD 10:30 – 11:05 Break 11:05 - 12:10 pm POD II – Advancing Practice 11:05 – 11:30 am Obesity & Inflammation: Weight Management in Rheumatology Uzma Haque, MD 11:30 - 11:55 am Mitigating risk in Rheum Pts undergoing surgery Susan Goodman, MD 11:55 -12:10 pm Practice Panel Faculty Q&A 12:10 – 1:00pm Lunch 1:00 – 3:00 pm POD III – Decisions in Psoriatic Arthritis 1:00 - 1:30 pm Paradoxical Psoriasis and Strange Reactions Joseph Merola, MD 1:30 - 2:00 pm Why Do Plain X rays in Psoriatic Arthritis Arthur Kavanaugh, MD 2:00 - 2:30 pm IL-23 vs IL-17 inhibitors in PsA Andre Ribero, MD 2:30 - 3:00 pm Past, Present & Future of Gout Robert Terkeltaub, MD 3:00 - 3:30 pm Psoriatic Faculty Q&A 3:30 - 4:05 pm Break 4:05 - 4:20 pm STEP 3: Helicobacter Pylori update Byron Cryer, MD 4:20 - 4:35 pm STEP 4: History of Gout Robert Terkeltaub, MD 4:35 – 5:15 pm Keynote Address: 50 Years of Osteoporosis Michael McClung, MD 5:30 – 7:00 pm Reception Sunday, February 8, 2026 Day TOPIC Speaker 7:50-8:00 am Welcome & Introductions Drs. Cush and Kavanaugh 8:00 - 10:00 am POD IV – Staying Ahead of Spondyloarthritis 8:00 – 8:30 am Diagnosing Axial Spondyloarthritis in 2026 Denis Poddubnyy, MD 8:30 – 9:00 am Spondyloarthritis Complications Jessica Walsh, MD 9:00 – 9:30 am 2026 Advances in Spondyloarthritis Catherine Bakewell, MD 9:30 – 10:00 am Spondyloarthritis Faculty Q&A 10:00 – 10:15 am STEP 5: Asymptomatic Elevation of CK Rojit Agarwal, MD MS 10:15 – 10:30 am STEP 6: Update on Myositis Antibodies Rojit Agarwal, MD MS 10:30 – 11:05 am Break 11:05 – 12:10 am POD V – Highlights in Autoimmune Disease 11:05 - 11:35 am SMILE Study – Hydroxychloroquine in ANA+ Arthralgia Nancy Olsen, MD 11:35 – 12:05 am Sjogren's Treatment Landscape in 2026 Matthew Baker, MD 12:05 - 12:20 pm Autoimmune Faculty Q&A 12:20 – 1:25 pm POD VI - Large & Small Vessel Vasculitis 12:20 – 12:45 pm Embracing Relapses in PMR and GCA Michael Putman, MD 12:45 - 1:10 pm Small vessel vasculitis Clay Cockerell, MD 1:10 - 1:25 pm Vasculitis Faculty Q&A 1:30 pm Adjourn

QD Clinics - Mission: APP Partners in Care Week 1

Sun, 07 Dec 2025 12:51:11 -0600

QD300: Flare or Beware (featuring Lindsay Tom, PA-C and Phong Nguyen, MD) QD301: CAR-T Cell Therapy for Lupus (featuring Philip Mease, MD and Cayla Alexander, DNP) QD302: Unweanable PMR (featuring Jack Cush, MD, and Leilani Law, APN) QD303: Weakness with Fibromyalgia (featuring Jack Cush, MD, and Leilani Law, APN)

APPs in the news (12.05.25)

Fri, 05 Dec 2025 07:36:17 -0600

Dr. Jack Cush reviews the news and journal reports from RheumNow.com, including info on scleroderma, dermatomyositis and malignancy, rheumatologist and APP salaries concerns.

Hiring, Onboarding and Training APPs

Wed, 03 Dec 2025 12:53:30 -0600

Watch our kickoff webinar for this month's Mission: APP — Partners in Care campaign. Our panel of rheumatologists and experienced advanced practice providers share insights into hiring, onboarding, training, compensation, and more.

Panelists:
Philip Mease, MD
Cayla Alexander, DNP, ARNP
Kori Dewing, DNP, ANP-BC, ARNP
Jack Cush, MD, Moderator

Turkey Tryptophan (11.28.2025)

Fri, 28 Nov 2025 18:14:55 -0600

Dr. Jack Cush reviews the news and reports from this past week on RheumNow.com, including reports on FDA resurrections, FM seasonal worsening, and do you fight switch or swap biologics in PsA TNFi nonresponders?

DERM on RheumNow (November 2025)

Wed, 26 Nov 2025 09:33:56 -0600

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.
Features Dr. Jack Cush, Editor at RheumNow.com.
SHOW NOTES
1. Retrospective study of 39 pts w/ MDA5 + DM-ILD Rx w baricitinib. 31 (79.5%) had improvement in Gottron’s, heliotrope, dyspnea, HRCT score, ferritin, LDH, steroid dose & 6 mo survival (87% vs. 70%, p = 0.047). https://t.co/RCTbBsCkeV
2. Pulse Steroids and Mycophenolate in Juvenile Dermatomyositis JAMA Dermatology has published a pilot study demonstrating the safety and efficacy of intermittent intravenous methylprednisolone pulse (IVMP) therapy plus mycophenolate in 28 patients with JDM. https://t.co/i2HBycbWY9
3. Myelodysplastic & chr myelomonocytic leukemia pts rarely get lupus. Review of 19 w/ SLE & 5 w/ CLE; these were older (65 yrs), more male (15M/9F), w/ less renal [10%] & articular [36%] Dz w/ less dsDNA [32%]. Thought to be clonal inflammatory, & not autoinflammatory, process. https://t.co/EAvkJm6GQs
4. Serious infections w/ adalimumab. Marketscan MarketScan claims study (1/17-12/20) of ADA Rx in Hidradenitis Supprativa (n 1650) or psoriasis(8699). Risk of SIE & hospitalization greater w/ HS (HR 1.53); esp for sepsis & GU infxnhttps://t.co/2qa7O2v6fm
5. No risk of MACE seen w/ initiation of IL-17(R)A inhib. French study of 34 241 ipts Rx IL-17(R)Ai and 381 MACEs. MACE risk was not elevated (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitors. https://t.co/WcjgRhr8mj
6. Genetic Risks and Severe Cutaneous Reactions to Allopurinol A matched cohort study shows that HLA-B*58:01 and HLA-A*34:02 are strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), these alleles were absent in more than one-third of those https://t.co/NLpHVhr9Ww
7. Western Australia study of 1854 SLE pts (median 40 yrs old). Interstitial lung disease was seen in in 3.8% of SLE, 26 fold more than controls. Risk factors for ILD included older age, smoking and serositis. SLE-ILD pts had higher mortality rates (MR 52.0, CI 37.0–71.1).
8. 25-Hydroxyvitamin D levels and Lupus Outcomes Lupus patients entering a prospective cohort study with low vitamin D levels faced doubled all-cause mortality risk and tripled risk for major cardiovascular events during follow-up averaging 6 years, researchers said. https://t.co/CYwVy7ls7y
9. ACR2025 Non-Renal Lupus Guidelines – from ACR Convergence 2025
10. 900,000 vs 9 It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed. It takes less than nine minutes to make your patient feel seen, understood and reassured. If you skip the 9 minutes, you wasted the 900,000 https://t.co/o7BaWjS4HB

Tuesday Nite Rheumatology (on 11.25.25)

Wed, 26 Nov 2025 09:29:06 -0600

Replay of RheumNow Live 2025 - Vasculitis
Featuring:

- Dr. Michael Wechsler: Management of EGPA in 2025
- Dr. Rennie Rhee: Imaging in Vasculitis
- Dr. Richard Conway: Modern Treatment of PMR

Vitamin D and Lupus Outcomes (11.21.2025)

Fri, 21 Nov 2025 14:39:04 -0600

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Check out:
RNL 2026 – Feb 7 8 2026 DFW
RheumNow.live

Tuesday Nite Rheumatology (on 11.18.25)

Wed, 19 Nov 2025 07:50:26 -0600

Replay of RheumNow Live 2025 - Spondyloarthritis
Sponsored by AbbVie

Featuring:
Dr. Desiree van der Heidje - Advances in Treatment of Spondyloarthritis
Dr. Jennifer Cather - Progress in Hidradenitis Supprativa
Dr. Catherine Bakewell - Imaging Evaluation of Spondyloarthritis

Treating During Pregnancy (11.14.2025)

Fri, 14 Nov 2025 13:27:43 -0600

TNR 11.11.2025 - Replay of RheumNow Live 2025 - Psoriatic Arthritis

Thu, 13 Nov 2025 18:16:40 -0600

Replay of RheumNow Live 2025 - Psoriatic Arthritis
Sponsored by AbbVie

Featuring:
Dr. Alexis Ogdie - Can Aggressive Treatment of Psoriasis Prevent PsA?
Dr. Artie Kavanaugh - Combination Biologic Therapies in PsA
Dr. Kenneth Gordon - Head-to-head Studies in Psoriatic Disease – What have we learned?

TNR 11.6.2025 - Replay of RheumNow Live 2025 - Rheumatoid Arthritis

Thu, 13 Nov 2025 18:11:50 -0600

Featuring:
Dr. Jeffrey Curtis: AI applied to Rheumatoid Arthritis Care: Practically (Not) Perfect
Dr. Una Makris: Key Considerations When Managing Older Adults with RA
Dr. Bryant England: Who will manage multimorbidity in RA

A JAKi in GCA- Phase 3 Results Through 2 Years

Sun, 09 Nov 2025 08:57:53 -0600

A JAKi in GCA- Phase 3 Results Through 2 Years
Sponsored by AbbVie Medical Affairs + Health Impact

The Interview (11.7.2025)

Fri, 07 Nov 2025 18:21:10 -0600

ACR 2025 SpA Topic Panel

Thu, 06 Nov 2025 06:31:11 -0600

A focused discussion on updates in spondyloarthritis, including emerging data, treatment strategies, and real-world care considerations. Hear expert perspectives and practical takeaways shaping SpA management today.

ACR 2025 CAR-T Topic Panel

Tue, 04 Nov 2025 18:24:21 -0600

A focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping CAR-T practice right now.

ACR 2025 RA Topic Panel

Mon, 03 Nov 2025 19:27:18 -0600

A focused conversation on the latest in psoriatic arthritis care — from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping PsA practice right now.

ACR 2025 PsA Topic Panel

Sun, 02 Nov 2025 18:26:07 -0600

A focused conversation on the latest in psoriatic arthritis care - from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping PsA practice right now.

RheumNow Rheumatology Round-Up

Fri, 31 Oct 2025 14:07:49 -0500

Stay plugged into the conversations, discoveries, and breakthroughs moving rheumatology forward. Real updates. Real context. For clinicians who never stop learning.

A Halloween ACR Guidance (10.31.25)

Fri, 31 Oct 2025 13:03:50 -0500

Dr. Jack Cush recaps ACR2025 with suggestions on how to best learn ACR25 content from RheumNow.com and our Videos and podcasts.

ACR 2025 Daily Podcasts Day4c

Thu, 30 Oct 2025 14:45:27 -0500

NEPTUNUS: Ianalumab in Sjogren's

Pulmonary hypertension in Sarcoidosis

ACR 2025 CAR-T Topic Podcasts Compilation 2

Thu, 30 Oct 2025 14:34:35 -0500

Restoring B Cell Compartments with CAR T: Molecular Data is Here

CAR-T: The Future

ACR 2025 SpA Topic Podcasts Compilation 2

Wed, 29 Oct 2025 21:07:47 -0500

Revised Classification Criteria in axSpA https://www.youtube.com/watch?v=voFJrQo1ANU

NSAID Addition Helps the Spine but not the Hips https://www.youtube.com/watch?v=wTKMC1MTwpE

Biomarker Discovery in axSpA https://www.youtube.com/watch?v=X8Sc_3oBSVA

Sexual Function in axSpA https://www.youtube.com/watch?v=r4_Nsh7e_oo

Coping Strategies in axSpA https://www.youtube.com/watch?v=z9KdNuOu4nI

"ROC-SpA Study" https://www.youtube.com/watch?v=kIEN39XRsSM

Why do patients stay in clinical trials? https://www.youtube.com/watch?v=pVIBoN0jO2o

What to do after first TNR failure in axSpA? https://www.youtube.com/watch?v=PVSyq_Y5-PE

ACR 2025 RA Topic Podcasts Compilation 6

Wed, 29 Oct 2025 20:43:12 -0500

ILD in Patients with Connective Tissue Disease

Fiber and Methotrexate

RA ILD Prediction: simple as a dipstick?

"Leftover Pain in Inflammatory Arthritis"

ACR 2025 PsA Topic Podcasts Compilation 6

Wed, 29 Oct 2025 20:29:43 -0500

From Pain to Wellness in PsA

Secukinumab vs Ustekinumab in PsA

Izokibep: still enthused about enthesitis?

Using Digital Apps to Modify Pain in axSpA

ACR 2025 Daily Podcasts Day4b

Wed, 29 Oct 2025 20:15:57 -0500

"ROC-SpA Study"

Secukinumab vs Ustekinumab in PsA

RA ILD Prediction: simple as a dipstick?

Sjogren's Disease: PROs as a Filter for Precision Medicine

Why do patients stay in clinical trials?

Using Digital Apps to Modify Pain in axSpA

IgG4: Rare but Treatable!

ACR 2025 Daily Podcasts Day4a

Wed, 29 Oct 2025 20:02:06 -0500

From Pain to Wellness in PsA

IL-2 Therapy in SLE? Maybe

Sexual Function in axSpA

"Fact or Fiction: Trinetics Research at ACR"

CD1/BCMA Dual Targeting: One too many targets in SLE

Hydroxychloroquine Blood Levels

The Great Debate: AI in Rheumatology

Coping Strategies in axSpA

"What to do After First TNR Failure in axSpA"

Day 4 Recap- ACR Convergence 2025 Highlights

Wed, 29 Oct 2025 19:29:13 -0500

Join panelists Drs. Brian Jaros, Akhil Sood and Michael Putman as they recap highlights from Day 4, the final day of the 2025 ACR Convergence meeting in Chicago.

Day 3 Recap- ACR Convergence 2025 Highlights

Wed, 29 Oct 2025 08:57:31 -0500

Join RheumNow Faculty Drs. Shelia Reyes, Mike Putman, Bella Mehta, and Jack Cush as they discuss highlights and key takeaways from the Day 3 Recap, at the 2025 ACR Convergence meeting in Chicago.

ACR 2025 RA Topic Podcasts Compilation 5

Wed, 29 Oct 2025 04:59:24 -0500

Screen RA ILD Properly

Rheumatoid Arthritis Highlights

Predicting Rheumatoid Arthritis

GDF-15: How Depression is Related to Lung Disease in RA

ACR 2025 PsA Topic Podcasts Compilation 5

Wed, 29 Oct 2025 04:49:48 -0500

"Leftover Pain in Inflammatory Arthritis"

Another Specialized Biomarker in PsA

Secrets and Pearls in Rheumatology

What's the latest in PsA?

ACR 2025 Daily Podcasts Day3c

Wed, 29 Oct 2025 04:18:36 -0500

GDF-15: How Depression is Related to Lung Disease in RA

What Can we do About Chronic Pain?

What's the latest in PsA?

What to do after first TNR failure in axSpA?

ACR 2025 Daily Podcasts Day3b

Wed, 29 Oct 2025 04:04:19 -0500

Secrets and Pearls in Rheumatology

Addressing Lupus Nephritis Timely

Fake Rheum Diagnostic Dilemmas

Rheumatoid Arthritis Highlights

Restoring B Cell Compartments with CAR T: Molecular Data is Here

Predicting Rheumatoid Arthritis h

What Causes Infection in Vasculitis?

Is it All About the Weight Loss?

Izokibep: still enthused about enthesitis?

T Cell Engagers: Are we engaged?

Fiber and Methotrexate

ACR 2025 Daily Podcasts Day3a

Wed, 29 Oct 2025 03:43:27 -0500

Spondyloarthritis: The CLASSIC Study

"Leftover Pain in Inflammatory Arthritis"

NeuroImmune Modulation in RA: Results of the RESET RA Trial

Change it or Keep it? TNF in Axial SpA

Perspectives on CAR T Therapy

Addressing Lupus Nephritis Early

Addressing Lupus Nephritis Aggressively

CAR-T: The Future

Biomarker Discovery in axSpA

Another Specialized Biomarker in PsA

Revised Classification Criteria in axSpA

ACR 2025 SpA Topic Podcasts Compilation 1

Tue, 28 Oct 2025 12:44:53 -0500

Catching AxSpA Early: Closing the Diagnostic Gap

Early Peripheral SpA: Is it okay to stop treatment sometimes?

Difficult to Manage axSpA

Tofacitinib in AxSpA in Developing Countries

Late-Breaking Trials in axSpA and PsA

Durability and Safety of Bimekizumab

Biologics Improve Sexual Function in axSpA

Multidimensional Pain inventory in Axial SpA

Spondyloarthritis: The CLASSIC Study

Change it or Keep it? TNF in Axial SpA

"Leftover Pain in Inflammatory Arthritis"

ACR 2025 CAR-T Topic Podcasts Compilation 1

Tue, 28 Oct 2025 11:54:59 -0500

B Cell Depletion: Check the Lymph Node

"Next Generation T-Cell Engager: The Future"

Off the Shelf: CAR-T

Combining CAR-T with CAR-Treg All in One

CAR-T Therapy: Where is it Heading?

Safety of CAR-T

New Paradigms in RA Treatment

Perspectives on CAR T Therapy

ACR 2025 RA Topic Podcasts Compilation 4

Tue, 28 Oct 2025 10:32:30 -0500

Wired for Success: Vagal Nerve Therapy in RA

RA: Does upfront TNFi save heartache?

New Paradigms in RA Treatment

ACR 2025 RA Topic Podcasts Compilation 3

Tue, 28 Oct 2025 10:25:12 -0500

SLGT-2 and GLP-1 in RA: More than Weight Loss

ACR2025 Day 1 RECAP

ACR 2025 RA Topic Podcasts Compilation 2

Tue, 28 Oct 2025 10:13:00 -0500

Cellular Biomarkers of Rheumatoid Arthritis

Day 2 Recap: ACR Convergence 2025 Highlights

ACR 2025 RA Topic Podcasts Compilation 1

Tue, 28 Oct 2025 10:01:34 -0500

STOP RA Cellular & Serologic Predictors

Rheumatoid Arthritis: Inject the Steroids

Is Low Disease Activity Low Enough?

ACR 2025 PsA Topic Podcasts Compilation 4

Tue, 28 Oct 2025 09:07:10 -0500

Catching PsA before it Starts

Day 2 Recap: ACR Convergence 2025 Highlights

ACR 2025 PsA Topic Podcasts Compilation 3

Tue, 28 Oct 2025 08:59:46 -0500

PsA and Brain Fog

GLP-1 Receptor Agonists in PsA: Mortality and MACE

PsA Predictors

When the Back Hurts: uncovering BASDAI drivers in PsA

The Upper Hand in PsA? Not the Dominant One

ACR 2025 PsA Topic Podcasts Compilation 2

Tue, 28 Oct 2025 08:46:12 -0500

Diagnostic Delays in PsA: A Radiographic Perspective

Late-Breaking Trials in axSpA and PsA

New Approaches to Therapy in PsA

ACR 2025 PsA Topic Podcasts Compilation 1

Tue, 28 Oct 2025 07:17:05 -0500

Psoriatic Arthritis Imaging

Specialized Biomarkers in PsA

PsA: Impact of Sex

GLP-1 and SGLT-2: Treatments Too Good to Ignore?

ACR 2025 Daily Podcasts Day2d

Mon, 27 Oct 2025 22:13:05 -0500

Safety of NSAIDs in Inflammatory Bowel Disease

Screen RA ILD Properly

Biologics Improve Sexual Function in axSpA

Catching PsA before it Starts

Multidimensional Pain inventory in Axial SpA

RA: Does upfront TNFi save heartache?

Novel Insights into Sjogren's Disease

New Paradigms in RA Treatment

Biomarkers in Still's and Macrophage Activation Syndrome

"The Power of Gamma Delta T Cell for Autoimmunity"

The Heartbreak of Sarcoidosis

ACR 2025 Daily Podcasts Day2c

Mon, 27 Oct 2025 21:51:10 -0500

NSAID Addition Helps the Spine but not the Hips

Durability and Safety of Bimekizumab

Progressive BiTE in SLE 2

Hydroxychloroquine Reduces Autoantibody Levels

When the Back Hurts: uncovering BASDAI drivers in PsA

The Upper Hand in PsA? Not the Dominant One

Airway Disease in GPA

Wired for Success: Vagal Nerve Therapy in RA

GLP-1 in Knee Osteoarthritis

Disparities in Physical Function in SLE

ACR 2025 Daily Podcasts Day2b

Mon, 27 Oct 2025 20:36:31 -0500

Putting Steroid Tapering into Practice in SLE

Tocilizumab Beats Methotrexate in GCA

GLP-1 Receptor Agonists in PsA: Mortality and MACE

Safety of CAR-T

ILD in Patients with Connective Tissue Disease

SLGT-2 and GLP-1 in RA: More than Weight Loss

PsA Predictors

Ianalumab: Breakthrough Therapy in Sjogren's

ACR 2025 Daily Podcasts Day2a

Mon, 27 Oct 2025 20:16:26 -0500

Off the Shelf: CAR-T

Combining CAR-T with CAR-Treg All in One

Tapering in SELECT GCA: Steroids are the Problem

Diagnostic Delays in PsA: A Radiographic Perspective

Late-Breaking Trials in axSpA and PsA

New Approaches to Therapy in PsA

PRED-SAFE: Chronic Prednisone Use

PsA and Brain Fog

CAR-T Therapy: Where is it Heading?

Day 2 Recap- ACR Convergence 2025 Highlights

Mon, 27 Oct 2025 19:51:14 -0500

Join RheumNow Faculty Drs. David Liew, Antoni Chan, Mrinalini Dey, and Jack Cush as they discuss highlights and key takeaways from the Day 2 Recap on Monday, October 27th, at the 2025 ACR Convergence meeting in Chicago.

ACR 2025 Daily Podcasts Day1c

Mon, 27 Oct 2025 17:18:15 -0500

A Nose for Vasculitis: ENT Manifestations in ANCA-Associated Disease

Tofacitinib in AxSpA in Developing Countries

Specialized Biomarkers in PsA

B Cell Depletion: Check the Lymph Node

GLP-1 and SGLT-2: Treatments Too Good to Ignore?

Nerandomilast for ILD

PsA: Impact of Sex

Cellular Biomarkers of Rheumatoid Arthritis

Using AI and LLMs in Qualitative Data

Belimumab Before or After Immunosuppressant

Do Patients with Rheumatic Diseases 'Weather' the Storm?

AI in Fellow Recruitment: A New Dawn in Medical Education?

ACR 2025 Daily Podcasts Day1b

Mon, 27 Oct 2025 11:42:25 -0500

AI Scribes Found their Favorite Doctors

Hospitalization in Stills: Is it "Still" an Infection?

Upadacitinib is a Double Edged Vascular Sword in GCA

Rheumatoid Arthritis: Inject the Steroids

Catching AxSpA Early: Closing the Diagnostic Gap

Is Low Disease Activity Low Enough?

Early Peripheral SpA: Is it okay to stop treatment sometimes?

Difficult to Manage axSpA

ACR 2025 Daily Podcasts Day1a

Sun, 26 Oct 2025 20:21:57 -0500

STOP RA Cellular & Serologic Predictors Is AI Smarter than a Doctor? Lung Disease in ANCA-associated Vasculitis Older Adults Underrepresented in RCTs Next Generation T-Cell Engager: The Future Lupus in Focus: 2025 ACR Treatment Guidelines for SLE Psoriatic Arthritis Imaging

ACR2025 Day 1 RECAP

Sun, 26 Oct 2025 19:41:35 -0500

Big takeaways, standout moments, and what set the tone for this year’s conference. We break down the key insights, early trends, and conversations shaping Day 1.

Pre-ACR25 (10.24.2025)

Fri, 24 Oct 2025 15:59:06 -0500

Dr. Jack Cush reviews the news and info reports the day before ACR 2025.

DERM on RheumNow (October 2025)

Sat, 18 Oct 2025 15:14:54 -0500

DERM on RheumNow PODCAST (October 2025)
Skin important Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com.
SHOW NOTES
1. Skin Biopsies to Predict Scleroderma Outcomes?
2. Fibromyalgia in PsO & PsA is linked to greater treatment complexity and shorter biologic therapy survival. Retro matched 1:4 cohort study 61K PsO& 244K controls. FM prevalence 3.3% (OR 1.45). In PsA w/ FM, req more biologics w/ decr biologic survival (6 vs 10yrs) w/ incr switching (HR 1.82) https://buff.ly/TCc6Kc8
3. Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis https://rheumnow.com/news/guselkumab-fda-approved-pediatric-psoriasis-and-psoriatic-arthritis
4. Sonelokimab (SLK) is a nanobody that inhibits IL-17 A&F. Phase 2 ARGO trial 207 active PsA pts Rx w/ SLK 120-mg or 60-mg q4wks or PBO or adalimumab. ACR50 at wk 12 was 60-mg WI=46%; 120-mg WI=46%; PBO 20%. PASI90: 60mg 77% vs 120mg 59% vs PBO 15% https://t.co/ra0NqvUEru https://t.co/FXT6kkXUzH
5. Turkish study of 799 psoriasis pts - 30% had concurrent onset PsO & PsA & in 70% there was a long transition time (~13 yrs) from PsO-to-PsA. Factors assoc w/ prolonged interval included Depression, fatigue, scalp PsO(OR 7), nail PsO (3.2), +Fhx & enthesitis ever (OR 2) https://t.co/wqtSbeQ2vz
6. Mediterranean Diet Efficacy in Psoriasis
7. Gender Complexities in Psoriatic Arthritis Treatment Outcomes

Bad Actor Cofactor (10.17.2025)

Fri, 17 Oct 2025 08:35:50 -0500

Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.

Eating Crow (10.10.2025)

Fri, 10 Oct 2025 07:24:25 -0500

Associations in Rheumatology (10.3.2025)

Fri, 03 Oct 2025 10:51:53 -0500

Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.

ILD Diagnosis, Screening and Monitoring

Wed, 01 Oct 2025 07:54:52 -0500

Our final webinar in this month's Rheum to Breathe: ILD campaign brings together ILD experts to discuss best practices in diagnosis, screening, and monitoring, covering: tools, labs, and imaging; timing and frequency of screening; ILD screening in RA; and, referral strategies.

Panelists:
Shane Shapera, MD
Elana Bernstein, MD
Bryant England, MD
Moderator: Jack Cush, MD

A JAKi CHAT: Shared Decision-Making in RA Sponsored by AbbVie Medical Affairs + Health Impact

Wed, 01 Oct 2025 07:33:25 -0500

Experts Dr. Jeffrey Curtis and Dr. Kevin Winthrop discuss best practices for shared decision-making, how to talk with patients about the risks of poorly controlled RA, and ways to use a new tool for visualizing the long-term safety of a JAKi.

QD clinics on ILD - lessons from the Clinic #4

Tue, 30 Sep 2025 07:27:29 -0500

QD clinics on ILD - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign
ILD QD Clinic #4
ILD QD Clinics - Worsening Breathlessness in SSc ILD: The Pressure Is On
ILD QD clinics on ILD #1 - Be Careful What you Look For

Rheum + Pulm Collaborations in ILD

Mon, 29 Sep 2025 05:02:22 -0500

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 4: Rheum + Pulm Collaborations in ILD including The Rheumatologist and Pulmonologist: Different approaches to the same patient (Dr. Paul Dellaripa and Dr Rachel Putman).

ILD Assessment and Management

Mon, 29 Sep 2025 04:58:37 -0500

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 3: ILD Assessment and Management including: Biomarkers in ILD (Dr. Elena Joerns), How to Assess ILD in Patients (Dr. Janet Pope) and Management of SSc ILD (Dr. Alicia Hinze)

ILD Treatment

Mon, 29 Sep 2025 04:47:46 -0500

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 2: ILD Treatment including: RA-ILD Treatment Update (Dr. Bryant England), Do DMARDS Affect CTD-ILD Outcomes? (Dr. Elizabeth Volkmann), Non-pharmacologic Treatment of ILD (Dr. Jon Giles) and Transplantation: A real option! (Dr. John Joerns)

ILD Guidelines

Mon, 29 Sep 2025 04:34:52 -0500

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 1: ILD Guidelines including: ACR/CHEST Guidelines for SSc ILD (Dr. Sindhu Johnson), ERS/EULAR Clinical Practice Guidelines (Dr. Anna-Maria Hoffman-Vold) and ILD Guideline Caveats and Concerns (Dr. Jeffrey Sparks).

How Does Your Garden Grow (9.26.2025)

Fri, 26 Sep 2025 12:17:37 -0500

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Pool therapy, Fibrosis, NSIE's and whats best for knee OA.

QD clinics on ILD - lessons from the Clinic #3

Fri, 26 Sep 2025 03:22:10 -0500

QD clinics on ILD - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign

ILD QD Clinic #3
ILD QD Clinic: Application of the ACR CHEST Guidelines to Two Cases
ILD QD Clinic: Progressive RA-ILD Management
ILD QD Clinic: Beyond the Numbers in Newly Diagnosed ILD

Rheum to Breathe Journal Club

Wed, 24 Sep 2025 07:31:02 -0500

In this journal club, we will discuss two pivotal studies in ILD, the FIBRONEER study and the RECITAL study:

Nerandomilast in Patients with Progressive Pulmonary Fibrosis, Maher, T.M. et al. NEJM. 2025 May 19. doi: 10.1056

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial, Maher T.M., et al. Lancet 2023 Jan;11(1). doi: 10.1016

Panelists:
Toby Maher, MD
Shervin Assassi, MD
Jack Cush, Moderator

DERM on RheumNow Podcast (September 2025)

Sun, 21 Sep 2025 20:14:21 -0500

Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE, vasculitis, HS and dermatology drugs use, efficacy and side effects and more.
Features Dr. Jack Cush, Editor at RheumNow.com.
SHOW NOTES:
1. SMILE Study: A randomized, placebo-controlled trial of hydroxychloroquine in incomplete lupus https://t.co/NnrA8ohiGX
2. Equal Safety of JAK Inhibitors and TNF Inhibitors in H2H IMID trials JAMA systematic review. https://t.co/HI1KBKZiXR
3. SMART study - Single vs. Split Dose Methotrexate https://t.co/lizsrtVHwf
4. Vegan diets don’t work in RA - Metanalysis of 7 studies https://t.co/jeh6gN5Byg
5. No association between IL-17 inhibitors & MACEs (vs TNFi Rx) https://t.co/fJuPFYKnSr https://t.co/Vscnsq0DTA
6. Successful Phase 3 UP-AA Trial evaluating Upadacitinib in Alopecia Areata (AA) https://t.co/8p1FvJx0s0
7. Anifrolumab effective & safe in refractory Cutaneous LE - OL Study in 15 CLE https://t.co/umEYz0XDyt
8. "Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it's the only thing that ever has." - Margaret Mead https://t.co/OFGN223bPa

Big Fat FDA Pink Slip (9.19.2025)

Fri, 19 Sep 2025 10:52:56 -0500

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs wont do & an FDA Pink Slip.

Controversies in ILD

Thu, 18 Sep 2025 06:49:07 -0500

This deep dive into controversies in interstitial lung disease explored complex topics including IPAF, methotrexate, systemic autoimmune rheumatic disease vs. connective tissue disease distinctions, and the evolving role of anti-fibrotic therapy.

Panelists: Jeffrey Sparks, MD, Janet Pope, MD, Elena Joerns, MD
Jack Cush, MD - Moderator

APLAR Congress 2025

Wed, 17 Sep 2025 18:16:56 -0500

Dr. Peter Nash, Australia, reports highlights from a range of sessions presented at the APLAR 2025 Congress in Fukuoka, Japan.

Hot Topics in AxSpA

Precision Medicine in PsA

PSA Therapeutic Update

CAR T Therapy with Immunomediated Diseases

Imaging Use of Micro CT Low Radiation for PsA

QD clinics on ILD - lessons from the Clinic

Mon, 15 Sep 2025 14:16:25 -0500

"QD clinics on ILD - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign.

Here are the individual video titles and links:

ILD QD Clinic: Stick or twist (when not to change treatment) https://youtu.be/sdGPsvcfyzQ

ILD QD Clinic: Interstitial Lung Disease with Positive SSA and Rash https://youtu.be/1H10_VR8t_0

ILD QD Clinic Video: RA and Bronchiectasis https://youtu.be/-StSi3v8ew8

Ro, Ro, Ro52 (9.12.2025)

Fri, 12 Sep 2025 07:38:01 -0500

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are their benefits to Diet/vegan diets? Whats the effect of menopause on CTD? Ro52 makes a big entrance with all our ILD coverage this month.

ILD and Autoimmune Disease

Thu, 11 Sep 2025 13:08:46 -0500

Rheum to Breathe “ILD and Autoimmune Disease”:
RA ILD Complications (Scott Matson): https://youtu.be/xTLvKLwlF-E
ILD and Mortality (Bryant England): https://youtu.be/Ew9OW2o43Bg
ILD in Sjorgen's (Nancy Cateron):https://youtu.be/BLVF2qvoR7E
Truth of Fake: Idiopathic Interstitial Pneumonia with Autoimmune Features (Janet Pope): https://youtu.be/4Jk7nVeLIR8

Future Treatment of ILD

Wed, 10 Sep 2025 09:14:16 -0500

This webinar will review the ACR and EULAR guidelines on interstitial lung disease, with a focus on ‘where are we now and where are we going?’ in regards to treatment strategies and emerging therapies in ILD care.
Panelists: Sindhu Johnson, MD Shane Shapera, MD Scott Matson, MD Jack Cush, MD - Moderator
https://youtube.com/live/Viexwyv0sxs?feature=share

QD clinics on ILD #1 - lessons from the Clinic

Tue, 09 Sep 2025 16:07:29 -0500

"QD clinics on ILD #1 - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign

September to Remember (9.5.2025)

Fri, 05 Sep 2025 06:32:44 -0500

Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogrens and alot of ILD.

Biologic Milestones & Future Treatment of RA

Tue, 02 Sep 2025 12:56:35 -0500

Join panelists as they discuss rheumatologist impressions, knowledge and practices over the last 20 years when treating rheumatoid arthritis. Experts will unpack the results of a nationwide, three-part survey — covering treatment milestones, changing practices, and what the future holds for RA therapy. Don't miss this opportunity to hear what your peers are saying — and where the field is headed.

Panelists:
Katherine Liao, MD, MPH
Stanley B. Cohen, MD
Jeff Curtis, MD, MS, MPH
Jack Cush, MD - moderator

ILD Begins (8.29.2025)

Fri, 29 Aug 2025 07:47:47 -0500

Dr. Jack Cush reviews the news and journal reports from RheumNow.com. This week news on vaccines, safety of acetaminophen and more.

Derm on RheumNow (Aug 2025)

Mon, 25 Aug 2025 17:22:28 -0500

Sjogrens Graduates (8.22.2025)

Fri, 22 Aug 2025 08:53:07 -0500

Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, etc.

Teaching You How to Think… (8.15.2025)

Fri, 15 Aug 2025 12:51:53 -0500

Dr. Jack Cush reviews the news, journal reports and press clippings from the past week on RheumNow. Positive results in a Sjogrens trial, to PT or not to PT, and aphorisms to live by.

Repurposing & Pipeline (8.8.2025)

Fri, 08 Aug 2025 06:32:00 -0500

Dr. Jack Cush reviews the news, reports, pipeline and drug repurposing on this weeks podcast.

Navigating the Path to SLE Remission

Mon, 04 Aug 2025 07:25:03 -0500

Rheumatologists Dr Anca Askanase and Dr Cristina Arriens discuss their clinical perspectives on how to target and achieve DORIS remission in clinical practice.
Sponsored by AstraZeneca Medical Affairs

A New RA Approval (8.1.2025)

Fri, 01 Aug 2025 11:25:43 -0500

Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.

CKD & Osteoporosis Rx Revisited (7.25.2025)

Fri, 25 Jul 2025 15:27:53 -0500

Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com

NHANES, Numbers, & Risk (7.18.2025)

Fri, 18 Jul 2025 07:59:29 -0500

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
Interesting case questions from "Ask Cush Anything"

Hmmm Really? (7.11.2025)

Fri, 11 Jul 2025 07:34:08 -0500

Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?

PCR- Prevalence, Cost, & Risk (6.27.2025)

Fri, 27 Jun 2025 10:46:53 -0500

Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com

EULAR 2025 Rheumatology RoundUp Hosted by Dr. John J. Cush and Dr. Arthur Kavanaugh

Wed, 25 Jun 2025 08:20:01 -0500

Join rheumatology experts Dr. John J. Cush and Dr. Arthur Kavanaugh for the EULAR Rheumatology RoundUp — a dynamic, fast-paced discussion capturing the most impactful highlights, late-breaking data, and clinical takeaways from EULAR 2025.

EULAR 2025 - Day 9 podcast

Tue, 24 Jun 2025 08:43:19 -0500

Trends and Innovations from Barcelona (6.20.2025)
AI Advances axSpA Diagnosis with Multimodal MRI
IL-17 Inhibitors in Psoriatic Arthritis
IL-17 Inhibitors for Axial Spondyloarthritis
New IL-17 Inhibition New Molecular Constructs

Trends and Innovations from Barcelona (6.20.2025)

Fri, 20 Jun 2025 07:14:01 -0500

EULAR 2025 - Day 8 podcast

Thu, 19 Jun 2025 21:40:01 -0500

Resilience or Resignation? Rethinking Pain, Aging, and Quality of Life
Spondyloarthritis Panel: Eular 2025

EULAR 2025 – SpA Panel Discussion

Thu, 19 Jun 2025 05:06:11 -0500

Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what’s new from EULAR 2025 and what it means for improving patient outcomes.

EULAR 2025 - Day 7 podcast

Wed, 18 Jun 2025 21:35:02 -0500

Digital Behavioural Therapy for Persistent Pain in Axial Spondyloarthritis
There's an App for That (and it works): the AXIA RCT

EULAR 2025 - Day 6 podcast

Tue, 17 Jun 2025 20:49:58 -0500

Eular 2025 PsA Topic Panel
Assessment of Peripheral Arthritis in Spondyloarthritis
IL-17 inhibitors - Novel Drugs
IL17 inhibitors - Long-term Extensions and Uveitis
IL17 inhibitors - STAMP T2T and Combinations
Using AI for Reading PET/CT in Rheumatoid Arthritis

Eular 2025 PsA Topic Panel

Tue, 17 Jun 2025 18:40:59 -0500

EULAR 2025 – RA Panel Discussion

Mon, 16 Jun 2025 19:42:15 -0500

Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don’t miss this in-depth panel as they unpack key findings from EULAR 2025 and discuss what’s next for RA care.

EULAR2025 Topic Podcast IL-17

Mon, 16 Jun 2025 11:35:30 -0500

Efficacy and Safety of Xeligekimab in AS
Sonelokimab in PsA
Seronegative Arthritis Breakthroughs
Novel Therapies in Axial Spondyloarthritis

EULAR2025 Topic Podcast RA2

Mon, 16 Jun 2025 10:51:53 -0500

JAK Inhibitors: The Latest from the JAK-pot Study
Does Abatacept Buy You Time Off RA?
How to Properly Use Steroids in Early RA: Oral vs Parenteral
All Rheumatoid Arthritis is Not the Same
Jekyll and Hyde: which RA-ILD is it?
RA treatment: A Constant State of Evolution

EULAR2025 Topic Podcast RA1

Mon, 16 Jun 2025 10:49:12 -0500

Who/When to Treat Clinically Suspect Arthralgia
Thoughtful, Effective RA Care Should be Guided by Need —Not Age
The Impact of Biologics on Methotrexate Adherence
Jokes Aside: The Impact of Laughter in RA
JAK Safety Update
Why is RA Difficult to Treat?
DMARD Combinations in RA Treatment
Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data
ALTO: Long-term Outcomes of APIPPRA

EULAR2025 Topic Podcast SpA

Mon, 16 Jun 2025 10:32:19 -0500

Efficacy and Safety of Xeligekimab in AS
Lessons on Uveitis and AxSpA
Difficult to Treat Axial Spondyloarthritis
MRI Lesions in Early axSpA vs Non-axSpA
Emerging Therapies in Axial Spondyloarthritis
Chronic Pain in AxSpA Beyond Fibromyalgia
Novel Therapies in Axial Spondyloarthritis
GLP 1 Receptor Agonists in axSpA Patients

EULAR2025 Topic Podcast PsA 2

Mon, 16 Jun 2025 10:21:12 -0500

Difficult to Treat Psoriatic Arthritis
Less or more frequent dosing in PsA?
Complex-to-Manage PsA: The GRAPPA Framework and Definition
Biologic Switching in PsA
Decoding Difficult to Treat PsA
Deucravacitinib in Psoriatic Arthritis: A New Oral Option with Dual Impact

EULAR2025 Topic Podcast PsA 1

Mon, 16 Jun 2025 10:18:50 -0500

EULAR 2025 - Day 1 podcasts
Sonelokimab in PsA
Seronegative Arthritis Breakthroughs
Using Combination csDMARDs in PsA
Deucravacitinib's Place in the PsA Treatment Algorithm?

EULAR 2025 - Day 5 podcast

Mon, 16 Jun 2025 08:25:33 -0500

Biologic Switching in PsA
Decoding Difficult to Treat PsA
Deucravacitinib in Psoriatic Arthritis: A New Oral Option with Dual Impact
GLP 1 Receptor Agonists in axSpA Patients
Jekyll and Hyde: which RA-ILD is it?
RA treatment: A Constant State of Evolution

EULAR 2025 - Day 4 podcast

Sat, 14 Jun 2025 19:04:28 -0500

Difficult to Treat Psoriatic Arthritis
Less or more frequent dosing in PsA?
Complex-to-Manage PsA: The GRAPPA Framework and Definition
Emerging Therapies in Axial Spondyloarthritis
Chronic Pain in AxSpA Beyond Fibromyalgia
Novel Therapies in Axial Spondyloarthritis
JAK Inhibitors: The Latest from the JAK-pot Study
Does Abatacept Buy You Time Off RA?
How to Properly Use Steroids in Early RA: Oral vs Parenteral
All Rheumatoid Arthritis is Not the Same

Daily Eular 2025 Recap Day 4

Sat, 14 Jun 2025 13:07:09 -0500

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the fourth day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.

EULAR 2025 - Day 3 podcast

Fri, 13 Jun 2025 21:33:03 -0500

Deucravacitinib's Place in the PsA Treatment Algorithm?
Lessons on Uveitis and AxSpA
Difficult to Treat Axial Spondyloarthritis
MRI Lesions in Early axSpA vs Non-axSpA
JAK Safety Update
Why is RA Difficult to Treat?
DMARD Combinations in RA Treatment
Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data
ALTO: Long-term Outcomes of APIPPRA

Daily Eular 2025 Recap Day 3

Fri, 13 Jun 2025 14:43:04 -0500

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the third day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.

EULAR 2025 - Day 2 podcast

Thu, 12 Jun 2025 20:32:13 -0500

Seronegative Arthritis Breakthroughs
Jokes Aside: The Impact of Laughter in RA
The Impact of Biologics on Methotrexate Adherence
Thoughtful, Effective RA Care Should be Guided by Need —Not Age
Sonelokimab in PsA
Using Combination csDMARDs in PsA

Eular 2025 Day 1/2 Recap

Thu, 12 Jun 2025 13:40:03 -0500

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the first day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.

EULAR 2025 - Day 1 podcasts

Wed, 11 Jun 2025 16:43:20 -0500

Efficacy and Safety of Xeligekimab in AS
Who/When to Treat Clinically Suspect Arthralgia

MTX Fails Knee OA (6.6.2025)

Fri, 06 Jun 2025 08:05:05 -0500

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Moneyball Rheumatology

Fri, 30 May 2025 07:08:16 -0500

Rx Update - Lupus Nephritis

Fri, 30 May 2025 07:04:00 -0500

New Steroid Rules for Lupus - Dr. Michelle Petri
Management of CKD in Lupus Nephritis - Dr. HJ Anders
HCQ Levels and Adherence - Dr. Nathalie Costedoat-Chalumeau
Lupus Nephritis Guidelines - a debate - Drs. Michelle Petri and Maria Dall'Era
Nephrologists Approach to Lupus Nephritis - Dr. Brad Rovin
Voclosporin and Steroids in Lupus Nephritis - Dr. Jack Cush

Lupus Unlocked- Pregnancy and SLE

Thu, 29 May 2025 10:53:32 -0500

In this webinar, panelists discussed issues such as congenital heart block, lupus nephritis treatment, teratogenic risks including conception on mycophenolate, antiphospholipid syndrome, hypertension management including the differential diagnosis of preeclampsia, practical guidance on pregnancy planning, and optimizing outcomes for patients with lupus.

Panelists: Dr. Megan Clowse, Dr. Lisa Sammaritano, Dr. Jill Buyon, Dr. Jack Cush

Lupus QD Clinics - lessons from the Clinic - Week 3

Mon, 26 May 2025 11:08:29 -0500

- QD286: Early Lupus (Dr. Jack Cush) https://youtu.be/zzpC397FhZ0
- QD287: A Different Strategy to Tackle Non-adherence (Dr. Megan Clowse) https://youtu.be/28fhFVM7QRc
- QD288: Tackling Lupus Pregnancies (Dr. Bella Mehta) https://youtu.be/zZiGyUTaEF0
- QD289: All Swells that Ends Well (Dr. Sheila Reyes) https://youtu.be/ipnSRchKLqY

Lupus QD Clinics - lessons from the Clinic - Week 2

Mon, 26 May 2025 10:59:07 -0500

- QD282: SLE Get Ready (Dr. Jack Cush) https://youtu.be/UWNAxiuwZro
- QD283: Rhupus (Dr. Jack Cush) https://youtu.be/OJUfylWJf4c
- QD284: The Dilemma of MMF Without Birth Control (Dr. Megan Clowse) https://youtu.be/Q1yJrQXyJSU
- QD285: Young SLE (Dr. Jack Cush) https://youtu.be/KigLAeOZciY

Lupus QD Clinics - lessons from the Clinic - Week 1

Mon, 26 May 2025 10:48:05 -0500

- QD279: Hyperpigmentation in Lupus (Dr. Jack Cush) https://youtu.be/xA9nvuadhCg
- QD280: Polar Opposite Approaches for Lupus (Dr. Eric Dein) https://youtu.be/zCnF1rgAapk
- QD281: Refractory Renal SLE (Dr. Jack Cush) https://youtu.be/dHS8etnZsRw

Diagnosing Neuropsychiatric SLE (5.23.2025)

Fri, 23 May 2025 13:30:20 -0500

Dr. Jack Cush reviews the news and journal reports from RheumNow.com - including views on the vagus nerve, NPSLE and CAR-T mania.

Lupus Unlocked- Antiphospholipid Syndrome

Wed, 21 May 2025 12:51:40 -0500

In this one-hour webinar, panelists discussed antiphospholipid syndrome, including diagnosis, labs, treatment approaches and more. Panelists Dr. Shruti Chaturvedi, Dr. Jason Knight, Dr. Cassy Sims and Dr. Jack Cush

Panacea of Prednisone & Cannabis (5.16.2025)

Fri, 16 May 2025 12:38:48 -0500

Dr. Jack Cush reviews the news, journal and regulatory reports from this week on RheumNow.com. Interesting trends and results with prednisone in lupus, cannabis in RA and opioid deaths too!

Lupus Unlocked- Cutaneous LE - Tuesday Night Rheumatology

Fri, 16 May 2025 09:27:29 -0500

Discussion of the diagnosis, management, and latest insights into cutaneous manifestations of SLE. Panelists: Dr. Victoria P. Werth, Dr. Matilda Nicholas; Dr. Anthony Fernandez; and, Dr. Christopher Richardson.

Vitamin D Headlines (5.9.2025)

Fri, 09 May 2025 08:05:16 -0500

Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow.com. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy.

Lupus Unlocked - Journal Club

Thu, 08 May 2025 12:37:44 -0500

In this first webinar of RheumNow's Lupus Unlocked campaign, Journal Club discussed two articles:

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Furie R, et al. NEJM. 2025 Feb 7. doi: 10.1056

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1) Rovin BH. Lancet. 2021 May 29;397(10289)

Speakers:
Brad Rovin, MD
Richard Furie, MD
Jack Cush, MD

Keys to Mastery (5.2.2025)

Fri, 02 May 2025 09:04:14 -0500

Dr. Jack Cush reviews the news, articles and drug approvals from the past week on RheumNow.com. This podcast marks the beginning of our Lupus Campaign called "Lupus Unlocked: Keys to Mastery". This months campaign on Lupus is sponsored by Aurinia.

A Phase 3 Trial of a JAKi in Patients With Giant Cell Arteritis Sponsored by AbbVie Medical Affairs + Health Impact

Thu, 01 May 2025 07:10:37 -0500

Listen as coinvestigator and rheumatologist Dr. Andrea Rubbert-Roth reviews this Phase 3 trial of a JAKi in patients with giant cell arteritis. Dr. Rubbert-Roth discusses the latest results, including efficacy and safety outcomes.

Rheumatology Believe It or Not (4.25.2025)

Sat, 26 Apr 2025 16:50:59 -0500

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Should we believe the reviews and metanalyses?

Osteoarthritis Risky Business (4.18.2025)

Fri, 18 Apr 2025 13:08:48 -0500

Dr. Jack Cush reviews the news and Journal reports from this week on RheumNow.com. Osteoarthritis patients have unique risks and synovial fluid WBC numbers can tell you when to worry about septic arthritis in gout and pseudogout patients.

EMR Messaging Woes (4.11.2025)

Fri, 11 Apr 2025 12:39:50 -0500

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com

An Epidural Letdown (4.4.2025)

Fri, 04 Apr 2025 08:01:55 -0500

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

**Correction: a Tweet from 3/18 podcast, had incorrect information. Late Breaking abstract from 2025 Amer. Acad. Dermatology (AAD) on the Phase 3 ICONIC-LEAD study showed J&J's oral IL-23 inhibitor (icotrokinra) was superior to PLACEBO (not deucravacitinib as reported) in skin clearance (65% vs 8%) & PASI90 (50% v 4%) at Wk 16 (NOT 15) in 684 moderate-to-severe plaque PsO pts https://buff.ly/dMbTbML

Biomarkers in RA

Tue, 01 Apr 2025 07:54:02 -0500

Rheumatologist Dr. Walter Maksymowych discusses the role of biomarkers in RA care, with a focus on 14-3-3eta as a modifiable marker for diagnosis and monitoring disease progression.

Cancer Survival with TNF Inhibitors (3.28.2025)

Fri, 28 Mar 2025 08:02:20 -0500

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

ERA, APPs, & Alpha GAL (3.21.2025)

Fri, 21 Mar 2025 08:59:58 -0500

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Listen in for 2 new case questions - Ask Cush Anything.

World Changers (3.14.2025)

Fri, 14 Mar 2025 07:55:29 -0500

Dr Jack Cush and his podcast friends are out to change the world. Here is his weekly review of the news and journal reports from the past week on RheumNow.com

Autoimmune Myositis The Role of the Laboratory in Diagnosis and Phenotyping Sponsored by LabCorp

Wed, 12 Mar 2025 16:47:15 -0500

Hear from rheumatologist Stanley J. Naides MD, FACP, FACR, as he details the clinical features of autoimmune myositis, the associated phenotypes and autoantibodies, plus the methodologies and testing options to support a myositis diagnosis.

EXXELERATE: New Thoughts on High RF Titer Sponsored by: UCB

Mon, 10 Mar 2025 08:10:42 -0500

Two leading rheumatologists share insights into why RF levels are important to consider when identifying treatment options for patients with RA.

Hydroxychloro-King (3.7.2025)

Fri, 07 Mar 2025 11:32:00 -0600

Dr. Jack Cush reviews the news, journal reports and regulatory actions from the past week on RheumNow.com

Treatment goals for RA- Is it time to transition to MOAs? Sponsored by AbbVie Medical Affairs

Sat, 01 Mar 2025 09:54:14 -0600

Opioid Deaths are Down (2.28.2025)

Fri, 28 Feb 2025 08:41:12 -0600

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Opioid deaths are down, IL-33 levels are up and Weight loss is in the news again this week!

B Cell Depleters (2.21.2025)

Fri, 21 Feb 2025 08:23:19 -0600

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Valentine RNL 2025 Review (2.14.2025)

Fri, 14 Feb 2025 07:13:55 -0600

Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025

Drug Naming Games (2.7.2025)

Fri, 07 Feb 2025 12:05:42 -0600

Dr. Jack Cush reviews the news, regulatory and journal reports from the past week on RheumNow.com

QD clinics - lessons from the Clinic - brought to you by RheumNow Live 2025

Fri, 31 Jan 2025 17:59:37 -0600

QD276 - New Palmoplantar Psoriasis and PsA https://youtu.be/GJmY27xA1MM

QD277 - dsDNA without Lupus https://youtu.be/daL70sBh8ss

QD278 - Recurrent Acute Oligoarthritis https://youtu.be/Xp2ZNBPN1o8

Features Dr. Jack Cush.

QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025

Participation is Up! (1.31.2025)

Fri, 31 Jan 2025 11:57:42 -0600

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

We have two call-in cases on "Ask Cush Anything"

Be sure to join in the fun at RNL 2025 next weekend - Gong Show Karaoke; what will you sing?

QD clinics - lessons from the Clinic brought to you by RheumNow Live 2025

Fri, 24 Jan 2025 12:43:41 -0600

QD Clinic 273 - ANA Negative Lupus https://youtu.be/g0W9aBRuDcQ
Pregnant ANA negative SLE (?) patients with Sjogrens and FM - what to do?

QD274 - Undiagnosed Autoinflammatory https://youtu.be/hUkYi1gKJOM
Autoinflammatory or Still's disease - does this matter?

QD275 - Past DIagnoses https://youtu.be/1f4HYhvVGNA
When patients cling to a past diagnosis.

QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at RheumNow.live

Weak Data (1.24.2025)

Fri, 24 Jan 2025 12:34:53 -0600

Dr. Jack Cush reviews the news and journal reports from RheumNow.com.
He features Dr. Charity Dean, the Keynote speaker at RheumNow Live 2025 and why she is an inspiration.
Register for RheumNow Live 2025 and hear Keynote Speaker, Dr. Charity Dean -- RheumNow.live

Fallen Angels (1.17.2025)

Fri, 17 Jan 2025 05:38:51 -0600

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.

QD clinics - lessons from the Clinic brought to you by RheumNow Live 2025

Mon, 13 Jan 2025 13:27:55 -0600

QD clinics - lessons from the Clinic brought to you by RheumNow Live 2025

QD 269 CREST or More? https://youtu.be/GSBfr2S9iL4
Is this CREST or Diffuse PSS?
Features Dr. Jack Cush.
QD270 Acute Neck & Back Pain https://youtu.be/qWTGvqL9-wY
Acute onset febrile, polyarthritis, neck and low back pain
Features Dr. Jack Cush.
QD271 - Treating Overlap with ILD https://youtu.be/eR7O-oy_O_g
Polyarthritis, ILD, Dermatomyositis - how to treat?
Features Dr. Jack Cush.
QD272 - Natural RA https://youtu.be/Ie1u-_KqxVE
PsO/PsA patient avoiding DMARDs and Biologics, and wants Natural therapies
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at RheumNow.live

Alive in 2025 (1.10.2025)

Fri, 10 Jan 2025 06:54:49 -0600

Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com

VITAL Info on Autoimmune Disease (1.3.2025)

Fri, 03 Jan 2025 14:29:58 -0600

Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "Youre No Good", and "How Long (has this been going on)".
From 2.9.2024

Bah Humbug Vitamin D (12.20.2024)

Fri, 20 Dec 2024 07:53:23 -0600

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

RheumNow Live 2025: Register now! RheumNow.live

54K Peptic Ulcers Annually (12.13.2024)

Fri, 13 Dec 2024 07:01:28 -0600

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com
Join us at RheumNow Live February 8 & 9 in Dallas, TX! https://t.co/7WawLxwBLP

Don’t Buy Guitars (12.6.2024)

Fri, 06 Dec 2024 08:43:44 -0600

This year at ACR24, the RheumNow faculty and reporters were prolific, generating 800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR 2024 by A) Rheumatology Roundup; b) TOPIC Panel podcasts; and c) Topic podcasts.

This weeks notable citations on RheumNow.com

ACR24 IL-17 Topic Panel Advancing Care with IL-17 Pathway Insights

Thu, 05 Dec 2024 08:04:36 -0600

Discover the latest advancements in targeting the IL-17 pathway from the ACR Annual Meeting! This expert-led panel will delve into groundbreaking research and therapeutic strategies for managing rheumatic diseases.

ACR24 JAK_TYK Topic Panel

Wed, 04 Dec 2024 07:23:29 -0600

Join us for an in-depth discussion about the ACR Annual Meeting! This expert panel will explore the latest research and clinical applications of JAK and TYK inhibitors in managing rheumatic diseases.

Stay informed about the cutting-edge therapies shaping the future of rheumatology care.

Dr. Janet Pope
London, Ontario

Dr. David Liew
Melbourne

Dr. Michael Putman
Milwaukee

ACR24 RA Panel Key Discussions on Rheumatoid Arthritis

Tue, 03 Dec 2024 07:31:19 -0600

Panelists: Dr. Jonathan Kay, Dr. Jiha Lee, Dr. Eric Dein and Dr. Jeffrey Spark

ACR24 PsA Topic Panel Advancing Care for Psoriatic Arthritis

Wed, 27 Nov 2024 07:11:28 -0600

Tune in for an engaging discussion at the ACR Annual Meeting! This expert panel will explore the latest breakthroughs and trends in Psoriatic Arthritis(PsA) research and management, providing actionable insights for clinicians and researchers.

ACR 2024 Rheumatology Roundup Featuring Drs. Artie Kavanaugh and Jack Cush

Wed, 27 Nov 2024 06:30:37 -0600

Highlight presentations from ACR 2024 in Washington, DC
Covered abstracts include:
- Dr. Kavanaugh
1679 Amplified & biomarkers
0082 Enthesitis Pathology & IL-23
1553 TLR 7/8 inhibitors in SLE
995 Carbon footprint to injectables
L20 ARTHUR DIANA Automated US
1132 VEGA (Combo Rx – see also 2640, 1460, 1393)
1745 Statin use in Oral Surveillance

- Dr. Cush
458 Seronegative RA fate
L19 Emapalumab in Stills disease
ACR 2024 updated guidelines on lupus nephritis
2580 Ianalumab in SLE
2259 Anti-Obesity Meds in RA
2657 Mortality with starting/stopping steroids
0774 TAPIR study in GCA
1697 PMR MODE study

ACR24 SpA Topic Panel Key Discussions on Spondyloarthritis

Tue, 26 Nov 2024 07:44:19 -0600

Join us as we dive into expert insights from the ACR Annual Meeting! This special panel will focus on the latest research and advancements in Spondyloarthritis (SpA), featuring thought leaders in the field.
Dr. Marina Magrey
Cleveland
Dr. Lihi Eder
Toronto
Dr. Sheila Reyes
Phillipines
Dr. Adela Castro
Memphis

ACR24 - RHEUMATOID ARTHRITIS

Mon, 25 Nov 2024 09:18:42 -0600

A New ACR
Cancer Survival in RA
"Changing Mindsets about Methotrexate Side Effects"
Control RA, Build Stronger Bones
Cumulative Steroid Use and Cardiovascular Events
Disease Activity in RA-ILD
Do TNFis and JAKis Prevent Cancer!?
Estimating Inflammation, Damage and Patient Distress
Finding the Right Combination Therapy in RA
Implantable Vagus Nerve Stimulator for RA
Is Frequent Lab Monitoring Necessary?
Long Term Follow up from APIPPRA
Metabolic Dysregulation and RA Interstitial Lung Disease
Native Americans with RA Die Young
Paraoxonase-1: Possible Biomarker for Progression to RA
Pred Softly: Steroids
Predicting Flares in Rheumatoid Arthritis
RA Roundup: Is LDA Inappropriate? What about Statins for JAKs?
RA Treatment Adherence: Is decision making really shared?
RA: One JAK to Rule Them All?
Sonelokimab in PsA: Phase 2 Data
Treat-to-Target Improves Fertility in Women with RA
Treatment Considerations for RA-ILD
Treatment Strategies in RA
Use of AI in Hand Ultrasound Scoring
Vaccine Responses:The DMARD Counts
What's New in Relapsing Polychondritis?
What's The State of Biosimilars?

ACR24 - IL-17

Sat, 23 Nov 2024 18:25:02 -0600

A New ACR
Anti IL-17 on Entheseal Biopsy in PsA
axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure
Best Things I Saw Today in PsA
Cycling vs Switching after TNFi Failure in axSpA
Improvements in Pain and Fatigue in Bimekizumab
Long-term Safety Profile of Bimekizumab in axSpA and PsA
Sonelokimab in PsA: Phase 2 Data
Treating SpA

ACR24 - JAK_TYK2

Sat, 23 Nov 2024 13:07:06 -0600

A New ACR
Best Things I Saw Today in PsA
Do TNFis and JAKis Prevent Cancer!?
Hold or continue JAKi and IL-17 when receiving COVID boosters?
JAK-pot! How fast do DMARDs work?
JAKi Studies at ACR
Poly-treatment of Polymyalgia Rheumatica?
RA Roundup: Is LDA Inappropriate? What about Statins for JAKs?
RA: One JAK to Rule Them All?
SELECT-GCA: Efficacy and Safety of Upadacitinib
"SELECT-GCA: Upadacitinib in Giant Cell Arteritis"
SELECTing the right patients: upadacitinib in GCA
So really, are JAKs Safe?
Summary of JAKi Studies
The Case for JAKi in PMR
The Real Value of JAKi is Beyond RA
When, What and How Long to Treat GCA & PMR
Worried about CV Risk and JAKi? What about the Steroids?

ACR24 - LUPUS

Fri, 22 Nov 2024 13:16:48 -0600

A Fibroblast Renaissance
A New ACR
A useful urinary biomarker for lupus nephritis
ANA+ and no Autoimmune Disease? Check the liver
CAR-T Therapy and Lupus
Cyclophosphomide vs Mycophenolate vs Tacrolimus in Lupus Nephritis
Evaluating ANA Patterns and Titers with AI
Neuropsychiatric Lupus: The Forgotten Symptoms
The 2024 ACR Guidelines for Lupus Nephritis
Vaccine Responses:The DMARD Counts
What is MCTD? The Great Debate

ACR24 - SPONDYLOARTHRITIS

Fri, 22 Nov 2024 12:46:51 -0600

A New ACR
Assessing ASAS Criteria: CLASSIC Study Results
Assessment and management of axSpA
Assessment of axSpA
Carotid Doppler Ultrasound Screening in Axial SpA
Cycling vs Switching after TNFi Failure in axSpA
Defining Difficult to Manage axSpA
Difficult to manage AxSpA
DISH in SpA
Gender Differences in AxSpA
Highlights in axSpA
Hot Topics in axSpA
Long-term Safety Profile of Bimekizumab in axSpA and PsA
Machine Learning for Predicting Flares in axSpA
Precision Immunotherapy in Axial SpA
PREDICT-SpA: Evaluating the influence of gender on disease assessment tools
Treating SpA
What is a Positive MRI in Spondyloarthritis?
axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure

ACR24 - PSORIATIC ARTHRITIS

Fri, 22 Nov 2024 10:53:18 -0600

A New ACR
Apremilast Benefits and Risks in PsA
Best Things I Saw Today in PsA
Bimekizumab in PsA Showed Sustained Reductions in Disease Impact
Biologic Monotherapy vs Combination with cDMARDs in PsA
Do TNFis and JAKis Prevent Cancer!?
Improvements in Pain and Fatigue in Bimekizumab
Long-term Safety Profile of Bimekizumab in axSpA and PsA
Potential Impact of Weight Loss Drugs in Rheumatic Diseases
Proposed ACR Guidance for Use of MSUS in Psoriatic Arthritis
PsA Potpourri
PsA Ultrasound Updates
PsA: Impact of Sex
Sex Differences in Psoriatic Arthritis
The Psoriatic March: PsA before PsO
Apremilast in PsA: Results from Mosaic Trial
Anti IL-17 on Entheseal Biopsy in PsA

ACR24 - Day4c

Fri, 22 Nov 2024 10:08:59 -0600

Is Frequent Lab Monitoring Necessary?:Dr. Bella Mehta
The Case for JAKi in PMR:Dr. David Liew
Treatment Strategies in RA:Dr. Victoria Konzett
What's New in Relapsing Polychondritis?:Dr. Bella Mehta
Worried about CV Risk and JAKi? What about the Steroids?:Dr. David Liew

ACR24 - Day4b

Wed, 20 Nov 2024 08:24:20 -0600

ANCA Vasculitis "Eye": Can rituximab help?:Dr. Janet Pope
Apremilast in PsA: Results from Mosaic Trial:Dr. Guillermo Valenzuela
Implantable Vagus Nerve Stimulator for RA:Dr. Guillermo Valenzuela
Treat-to-Target Improves Fertility in Women with RA:Dr. Richard Conway

RheumNow Day 4 Recap ACR Convergence 2024 Highlights

Wed, 20 Nov 2024 08:17:23 -0600

Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don’t miss our live coverage of key takeaways and trends shaping the future of patient care.

Join us live and stay at the forefront of rheumatology!

ACR24 - Day4a

Tue, 19 Nov 2024 11:05:18 -0600

ACR 24: What I learned in Sjogren's, Takayasu's and CAR-T:Dr. Janet Pope
Anti IL-17 on Entheseal Biopsy in PsA:Dr. Eric Dein
axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure:Dr. Brian Jaros
Can We Make Clinical Trials Better?:Dr. Janet Pope
Cumulative Steroid Use and Cardiovascular Events:Dr. Mrinalini Dey
IL 6 Inhibitors, Frailty and Polymyalgia Rheumatica:Drs. Trish Harkins and Sebastian Sattui
IVIG Treatment in Immune-mediated Necrotizing Myopathy:Drs. Caoilfhionn Connolly interviews Dr. Asim Mohamed
Machine Learning for Predicting Flares in axSpA:Dr. Sheila Reyes
So really, are JAKs Safe?:Dr. Janet Pope
Tackling the Workforce Crisis: A shared dilemma:Drs. Mrinalini Dey, Louise Pollard and Bharat Kumar
The 2024 ACR Guidelines for Lupus Nephritis:Dr. Sheila Reyes
The Real Value of JAKi is Beyond RA:Dr. David Liew
Vaccine Responses:The DMARD Counts:Dr. David Liew

RheumNow Day 3 Recap ACR Convergence 2024 Highlights

Tue, 19 Nov 2024 07:48:40 -0600

Join us live and stay at the forefront of rheumatology!

ACR24 -Day3b

Mon, 18 Nov 2024 21:56:16 -0600

Best Things I Saw Today in PsA:Dr. Catherine Bakewell
Do TNFis and JAKis Prevent Cancer!?:Dr. Richard Conway
Efficacy and Safety of Nipocalimab for Sjogren's Syndrome:Dr. Mike Putman
Evaluating ANA Patterns and Titers with AI:Dr. Bella Mehta
Improvements in Pain and Fatigue in Bimekizumab:Dr. Philip Mease
Long Term Follow up from APIPPRA:Dr. Antoni Chan talks with Dr. Andrew Cope
Race Neutral PFTs in Scleroderma Improves Equity:Dr. Caoilfhionn Connolly talks with Dr. Kamini Kuchinad
Summary of JAKi Studies:Dr. Peter Nash
The Psoriatic March: PsA before PsO:DR. Antoni Chan
Use of AI in Hand Ultrasound Scoring:Dr. Bella Mehta
What is MCTD? The Great Debate:Drs. Caoilfhionn Connolly & Lisa Christopher-Stine
What's The State of Biosimilars?:Drs. Eric Dein and Jonathan Kay
Pred Softly: Steroids:Dr. Jiha Lee talks with Dr. Beth Wallace

ACR24 - Day3a

Mon, 18 Nov 2024 11:25:23 -0600

Control RA, Build Stronger Bones:Dr. Jiha Lee talks with Dr. Rachel Elam
Hold or continue JAKi and IL-17 when receiving COVID boosters?:Dr. Bella Mehta
Long-term Safety Profile of Bimekizumab in axSpA and PsA:Dr. Philip Mease
Navigating Rheumatology Care in Humanitarian Crisis Settings:Dr. Antoni Chan talks with Dr. Martha Dhzhus
RA Roundup: Is LDA Inappropriate? What about Statins for JAKs?:Dr. Eric Dein
Sex Differences in Psoriatic Arthritis:Dr. Catherine Bakewell
Single v Double Lung Transplants for Disease-related ILD:Dr. Eric Dein talks with Dr. Harry Hurley
Sonelokimab in PsA: Phase 2 Data:Dr. Philip Mease
Treating SpA:Dr. Marina Magrey

ACR24 - Day2d

Mon, 18 Nov 2024 06:53:22 -0600

Assessment of axSpA:Dr. Antoni Chan
Defining Difficult to Manage axSpA:Dr. Lihi
DISH in SpA:Dr. Sheila Reyes
Generative AI in Rheumatology: The Good, The Bad, The Ugly:Dr. Akhil Sood
Native Americans with RA Die Young:Dr. Eric Dein
Precision Immunotherapy in Axial SpA:Dr. Marina Magrey
When, What and How Long to Treat GCA & PMR:Dr. Janet Pope

ACR24 - Day2c

Mon, 18 Nov 2024 06:44:35 -0600

A Fibroblast Renaissance:Dr. Andrea Fava
A useful urinary biomarker for lupus nephritis:Dr. Andrea Fava
ACR Advocacy Update:Dr. Eric Dein talks with Dr. Christina Downey, ACR Government Affairs Committee, and Dr. Kaitlyn Brittan, RheumPAC
Carotid Doppler Ultrasound Screening in Axial SpA:Dr. Trish Harkins discussed with Dr. Barry O'Shea
Enhanced Detection of Myocarditis in Idiopathic Inflammatory
Myopathies:Dr. Caoilfhionn Connolly talks with Dr. Julie Paik
PsA: Impact of Sex:Dr. Arthur Kavanaugh
Rethinking Lupus Care: Early Biologics, Less Steroids:Dr. Akhil
Treatment Considerations for RA-ILD:Dr. Jeff Sparks with Dr. Scott Matson

ACR24 Daily Recap Day2

Mon, 18 Nov 2024 06:09:14 -0600

Join us live and stay at the forefront of rheumatology!

ACR24 - Day2b

Sun, 17 Nov 2024 19:14:07 -0600

JAKi Studies at ACR:Dr. Peter Nash
Palliative Care in Rheumatology:Dr. Jiha Lee talks with Dr. Shannon Herndon
Estimating Inflammation, Damage and Patient Distress:Dr. Jack Cush talks with Dr. Ted Pincus
Methotrexate and the Gut Microbiome:Dr. Jonathan Kay talks with Dr. Rebecca Blank
Poly-treatment of Polymyalgia Rheumatica?:Dr. Janet Pope
Predicting Flares in Rheumatoid Arthritis:Dr. Jonathan Kay interviews Dr. John Isaacs
"Changing Mindsets about Methotrexate Side Effects":Dr. Mrinalini Dey
Biologic Monotherapy vs Combination with cDMARDs in PsA:Dr. Adela Castro
Cyclophosphomide vs Mycophenolate vs Tacrolimus in Lupus Nephritis:Dr. Mike Putman
ANA+ and no Autoimmune Disease? Check the liver:Dr. Janet Pope
SELECTing the right patients: upadacitinib in GCA:Dr. Brian Jaros
Neuropsychiatric Lupus: The Forgotten Symptoms:Dr. Mrinalini Dey talks with Dr. Chris Wincup

ACR24 - Day2a

Sun, 17 Nov 2024 12:51:36 -0600

Bimekizumab in PsA Showed Sustained Reductions in Disease Impact:Dr. Eric Dein talks with Dr. Ana-Marie Orbai
CAR-T Therapy and Lupus:Dr. Akhil Sood talks with Dr. Chris Wincup
Cycling vs Switching after TNFi Failure in axSpA:Dr. Lihi Eder
Difficult to manage AxSpA:Dr. Sheila Reyes talks with Dr. Denis Poddubnyy
Gender Differences in AxSpA:Dr. Adela Castro
Metabolic Dysregulation and RA Interstitial Lung Disease:Dr. Mrinalini Dey
PsA Ultrasound Updates:Dr. Catherine Bakewell and Dr. Lihi Eder
SELECT-GCA: Efficacy and Safety of Upadacitinib:Dr. Richard Conway

RheumNow Day 1 Recap ACR Convergence 2024 Highlights

Sun, 17 Nov 2024 07:06:50 -0600

Join us live and stay at the forefront of rheumatology!

ACR24 - Day1c

Sat, 16 Nov 2024 21:39:10 -0600

Aging Gracefully in Managing Rheumatic Diseases:Dr. Mrinalini Dey interviews Dr. Elena Myasoedova
Apremilast Benefits and Risks in PsA:Dr. Akhil Sood
Assessing ASAS Criteria: CLASSIC Study Results:Dr. Adela Castro
Assessment and management of axSpA:Dr. Antoni Chan
Disease Activity in RA-ILD:Dr. Richard Conway
Finding the Right Combination Therapy in RA:Dr. Jonathan Kay interviews Dr. Ernest Choy
Highlights in axSpA:Dr. Marina Magrey
Hot Topics in axSpA:Dr. Marina Magrey
Proposed ACR Guidance for Use of MSUS in Psoriatic Arthritis:Dr.
Antoni Chan interviews Dr. Catherine Bakewell
PsA Potpourri:Dr. Arthur Kavanaugh
RA Treatment Adherence: Is decision making really shared?:Dr. Jonathan
Kay interviews Dr. Cécile Gaujoux-Viala
RA: One JAK to Rule Them All?:Dr. Brian Jaros
What is a Positive MRI in Spondyloarthritis?:Dr. Sheila Reyes interviews Dr. Walter Maksymowych

ACR24 - Day1b

Sat, 16 Nov 2024 18:11:05 -0600

JAK-pot! How fast do DMARDs work?:Dr. Mike Putman and Dr. Kim Lauper
Paraoxonase-1: Possible Biomarker for Progression to RA:Dr. Jonathan Kay
Potential Impact of Weight Loss Drugs in Rheumatic Diseases:Dr. Arthur Kavanaugh
PREDICT-SpA: Evaluating the influence of gender on disease assessment tools:Dr. Sheila Reyes
SELECT-GCA: Upadacitinib in Giant Cell Arteritis:Dr. Mike Putman
Too Many CAR-Ts for Horses?:Dr. Pope
Transplant-free Survival Predictors in Idiopathic Inflammatory Myopathies-ILD:Dr. Gaby Martinez

ACR2024 - Day1a

Sat, 16 Nov 2024 16:36:01 -0600

A New ACR:Dr. Cush
Are we under-monitoring in scleroderma ILD?:Dr. Janet Pope
Cancer Survival in RA:Dr. Eric Dein interviews Joshua Hsieh
Continuing or Stopping Low Dose Glucocorticoids in GPA:Dr. Mike Putman
COVID Associated Immune Disease:Dr. Len Calabrese
How to Master ACR Meetings:Dr. Cush

ACR 2024 Preview Podcast (11.15.2024)

Fri, 15 Nov 2024 08:08:08 -0600

ACR 2024 starts tomorrow; here are a few previews of Abstracts to be presented. Along with my recommendations of sessions you don’t want to miss.

Dr. Quotes (11.8.2024)

Fri, 08 Nov 2024 10:22:38 -0600

Dr. Jack Cush reviews the news and journal reports from this past week from RheumNow.com

Minimizing Steroids in Lupus Sponsored by AstraZeneca Medical Affairs Nov 01, 2024

Mon, 04 Nov 2024 06:30:05 -0600

Minimizing steroid use in patients with SLE. Learn more about when, why, and how to taper steroids and listen to experts, Dr Michelle Petri and Dr Leanna Wise, discuss key data and their clinical perspectives on these topics.

Happy Diwali (11.1.2024)

Fri, 01 Nov 2024 07:32:18 -0500

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Blue Collar Arthritis (10.25.2024)

Fri, 25 Oct 2024 08:22:02 -0500

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com

EMJ Podcast Interview with Dr. Jack Cush

Wed, 23 Oct 2024 15:27:16 -0500

This week, Jonathan is joined by John J Cush, from Dallas, Texas, USA. The two doctors explore novel treatment avenues for rheumatic diseases, and discuss the exciting potential of AI and telemedicine.

ANA+ consult (10.18.2024)

Fri, 18 Oct 2024 07:45:09 -0500

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com

Dot the "i," Cross the "t" (10.11.2024)

Fri, 11 Oct 2024 16:10:45 -0500

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Todays reports suggest where to look for help, especially with regard to pain.

Stop Counting Bugs (10.4.2024)

Fri, 04 Oct 2024 02:31:01 -0500

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com -- This weeks rants include the microbiome, PsA treatment choices and fishing for P-values in research.

RA Risk Radar: Heart Disease, Infection, and Malignancy Sponsored by AbbVie Medical Affairs

Tue, 01 Oct 2024 09:02:38 -0500

Rheumatologists Dr. Jeffrey Curtis and Dr. Jon Giles discuss the risk of comorbidities that can occur as a consequence of uncontrolled inflammation in RA

Which One is the Loneliest Number (9.27.2024)

Fri, 27 Sep 2024 11:03:08 -0500

Dr. Jack Cush reviews the regulatory approvals, announcements, guidelines and interesting journal articles from the past week on RheumNow.com. When not to use muscle relaxants, how frequent is loneliness in RA/PsA/SpA and when to refer patients with Still's disease..

I Cant Treat Ugly (9.20.2024)

Fri, 20 Sep 2024 08:09:58 -0500

Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.

Systemic Sclerosis Insights (9.13.2024)

Fri, 13 Sep 2024 05:26:52 -0500

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Linger on the Fingers (9.6.2024)

Fri, 06 Sep 2024 06:42:27 -0500

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
This week with a focus on fingers and better prescriptive follow through.

Earlier treatment with biologics to reduce the risk of organ damage in systemic lupus erythematosus (SLE) Sponsored by GSK US Medical Affairs

Sat, 31 Aug 2024 07:39:50 -0500

Learn about the importance of reducing organ damage and corticosteroid-associated toxicity in SLE, and how biologics may help to change the course of the disease by targeting its underlying mechanisms.

Running with Data (8.30.2024)

Fri, 30 Aug 2024 06:36:02 -0500

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com - including tips on steroids, MAS, and myositis testing.

All in the Family (8.23.2024)

Fri, 23 Aug 2024 07:55:35 -0500

Dr. Jack Cush picks highlight reports from the past week on RheumNow.com, with reports on the challenge of lupus nephritis, perplexing skin issues, you don't know JAK (about Tyk) and the value of a good family history.

Higher Cancer Rates (8.16.2024)

Fri, 16 Aug 2024 07:10:17 -0500

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, noting his concerns about diet, cancer, ILD, death and dosing challenges.

Depends on Where You’re Looking (8.9.2024)

Fri, 09 Aug 2024 07:13:31 -0500

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.

Lead with Lupus (8.2.2024)

Fri, 02 Aug 2024 11:11:32 -0500

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com - leading with lupus because everyone wants to know about lupus!

Are your patients with moderate to severe RA getting the appropriate dose?

Thu, 01 Aug 2024 10:35:16 -0500

RA Experts (Drs. Alvin Wells, Orrin Troum, Grace Wright, Aaron Broadwell) discuss dose response differences in this podcast sponsored by Genentech. Full Prescribing Information including BOXED WARNING. Portions of this recording have been edited using AI technology for clarity.

Location, Location, Location (7.26.2024)

Fri, 26 Jul 2024 09:22:45 -0500

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Location matters; Geo-rheumatology?

The Best Rheumatologists (7.19.2024)

Fri, 19 Jul 2024 07:57:26 -0500

This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.

Pollution and Autoimmunity (7.12.2024)

Fri, 12 Jul 2024 06:56:06 -0500

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Dead Words Eulogy

Sat, 06 Jul 2024 09:33:22 -0500

Dr. Jack Cush reviews the terms in rheumatology that should no longer be used in the field of rheumatology. This lecture is part of the RheumNow Live 2024 meeting, being held January 27-28, 2024 in Dallas, TX (and virtually).

Future Big BiTEs (6.28.2024)

Fri, 28 Jun 2024 11:25:26 -0500

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com

EULAR 2024 RA Topic Panel

Mon, 24 Jun 2024 15:50:42 -0500

Moderated by Dr. Jack Cush and featuring Drs. Aurelie Najm, David Liew and Jonathan Kay

EULAR 2024 SLE Topic Panel

Mon, 24 Jun 2024 15:48:04 -0500

Featuring Drs. Jack Cush, Yuz Yusof, and Andrea Fava

EULAR 2024 Psoriatic Arthritis Topic Panel

Mon, 24 Jun 2024 15:43:35 -0500

Moderated by Dr. Jack Cush and Featuring Drs. Eric Ruderman, Antoni Chan, and Peter Nash

EULAR 2024 Rheumatology Roundup

Fri, 21 Jun 2024 08:02:31 -0500

Featuring Drs. Artie Kavanaugh and Jack Cush Discussion of highlights from the EULAR 2024 Meeting in Vienna

EULAR 2024 JAK/TYK Daily Topic Podcasts

Tue, 18 Jun 2024 10:05:03 -0500

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:
OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

Giant Cell Arteritis and Polymyalgia Rheumatica Update
Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria.

JAK Inhibitors for New Indications
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.

Pain in RA: Different Drugs for Different Mechanisms
Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086.

Top 3 Messages About JAK Inhibitor Safety
Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety.

DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop
Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria.

Has JAK POT Hit the Spot About Infection Risk?
Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria.

Select your GCA Therapy
Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.

EULAR 2024 SpA Daily Topic Podcasts

Tue, 18 Jun 2024 09:52:36 -0500

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:

OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter?
Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria.

OP0046 Effect on SI joint structural lesions with ixekizumab
POS0058 Effect on SI joint structural lesions with bimekizumab

Does Telemonitoring in SpA Work?
Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria.

Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.

Treat to Target Outcomes in Early AxSpA
Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria.

Early Diagnosis of Axial Spondyloarthritis
Dr. Antoni Chan reports on abstract OP0310 presented at Eular 2024 in Vienna, Austria.

Imaging in Axial Spondyloarthritis
Dr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria.

EULAR 2024 SLE Daily Topic Podcasts

Tue, 18 Jun 2024 08:50:36 -0500

Does B Cell Depletion Matter?
Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria.

3 Big Lupus Themes from EULAR 2024
Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria.
POS0732
OP0255

Voclosporin and Steroids in Lupus Nephritis
Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.

JAK Inhibitors for New Indications
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.

Cognitive Function in Older Adults with Lupus
Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria.

Does Withdrawing Steroids Increase Flares in SLE?
Dr. Janet Pope reports on abstract OP0180 presented at Eular 2024 in Vienna, Austria.

Tapering Treatment for Lupus
Dr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus.

The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity at Eular 2024 in Vienna, Austria.

We've Got to Talk about CAR T cells
Dr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria.

EULAR 2024 PsA Daily Topic Podcasts

Tue, 18 Jun 2024 08:38:18 -0500

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:

OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

JAK Inhibitors for New Indications
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.

PsA Treatment: is Earlier Better?
Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria.

Transition from Psoriasis to PsA: Can we Prevent It?
Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria.

Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA
Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria.

PsA Switch or Cycle, the Eternal Question
Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria.

Axial & Psoriatic Disease
Dr. Peter Nash at Eular 2024 in Vienna, Austria.

Difficult to Treat Psoriatic Arthritis
Dr. Peter Nash reports at Eular 2024 in Vienna, Austria.

Predictors of Treatment Response in Psoriatic Arthritis
Dr. Janet Pope reviews three abstracts presented at Eular 2024 in Vienna, Austria. Abstracts discussed:
POS 0990
POS 0992
POS 0266

Prevention of Psoriatic Arthritis
Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.

EULAR 2024 RA Daily Topic Podcasts

Tue, 18 Jun 2024 08:15:54 -0500

Mechanistic Promise in RA Doesn’t Always Mean Actual Gain
Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria.

The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis
Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309.

A Step Closer to Identifying Phenotypes of RA ILD
Dr. Mrinalini Dey discusses abstract OP0202 presented at Eular 2024 in Vienna, Austria.

Pain in RA: Different Drugs for Different Mechanisms
Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086.

Predicting Palindromic Prognosis
Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria.

Top 3 Messages About JAK Inhibitor Safety
Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety.

Abatacept Misses on Shingrix Response
Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria.

Artificial Intelligence Detection of CPPD on Hand Radiographs
Dr. Antoni Chan interviews Dr. Thomas Hugle about abstract OP0112 presented at Eular 2024 in Vienna, Austria.

Cognitive Function in Older Adults with Lupus
Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria.

Difficult-to-treat Rheumatoid Arthritis Validation of the EULAR Definition
Dr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria.

DMARDs and Herpes Zoster Vaccination To Stop or Not To Stop
Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria.

Has JAK POT Hit the Spot About Infection Risk?
Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria.

Inspirations About RA-ILD
Dr. Jonathan Kay discusses abstracts POS0070, POS0043 and POS0022 presented at the Eular 2024 meeting in Vienna, Austria.

Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA
Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria.

Digital Rheumatology
Dr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria.

Drug-resistant RA Does Blinatumomab BiTE?
Dr. Yuz Yusof reports on abstract OP0193, presented at Eular 2024 in Vienna, Austria.

EULAR Daily Podcasts Day 4

Mon, 17 Jun 2024 15:10:21 -0500